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Summary
Aim
In targeted radio ligand therapy determination of the regional distribution of the radiation
dose is mandatory for the development of therapy strategies which aim for maximizing the
therapeutic effect on the tumor, while reducing radiation exposure to healthy tissue. For
this purpose, after administration of the therapeutic agent, sequential measurements with
a scintillation camera are required to quantitatively assess the kinetics and distribution of
the radiopharmaceutical in the body. To improve the accuracy and robustness of existing
dosimetric concepts, the kinetic of Lu-177-DOTATATE, a radiopharmaceutical for the treatment
of patients with neuroendocrine tumors, was examined in depth. Subsequently, the findings
from this study were used to carry out the first image-based dosimetry for the new active
substance Lu-177-PSMA, a radiopharmaceutical for the treatment of patients with metastatic
prostate cancer. Due to the specific distribution pattern of this ligand, overlay effects in the
2-dimensional (2-D) planar projection were observed. Therefore a quantitative 3-dimensional
(3-D) SPECT imaging technique was established and optimized for dosimetry.
Methods
To characterize the dynamics of Lu-177-DOTATATE, whole-body planar projections of 105
patients were recorded at 1, 24, 48 and 72 h after injection. Furthermore, the first hour
beginning with the start of the therapeutic agent administration was measured in 12 time frames
with duration of 5 min each. An optimal dose model was introduced for the kidneys, for those
being a risk organ in this therapy, which consisted of three phases: a linear increase of tracer
accumulation during infusion, followed by a 2-phase model being described by a bi-exponential
decline. This full data model served as a basis for comparison with reduced data models based
on mono-exponentials which made use of all four (at 1, 24, 48 and 72 h after injection) or the
last three whole-body scintigraphies.
To support a successful determination of dosimetric values for the new radiopharmaceutical
Lu-177-PSMA in a patient study, methods which may overcome the observed activity overlap
in planar image projections were evaluated. The most promising approach was to make use of
quantitative 3-D SPECT, in which methods to correct for the attenuation of the photon flux,
the photon scattering due to electromagnetic interaction and the distance dependent detector
blur had to be implemented, followed by the application of a camera-specific calibration factor.
The quantitative 3-D SPECT technique was then evaluated for recovery of known activity by
a sphere-phantom and subsequently used to reconstruct patient images. Five patients with
metastasized prostate cancer received two cycles of Lu-177-PSMA therapy. To characterize and
quantify organ and tumor dose distribution caused by this radio therapeutic, patients were
imaged with 2-D whole-body scintigraphy and 3-D SPECT/CT at 1, 24, 48 and 72 h after
injection. Moreover, blood samples were collected for bone marrow dosimetry in accordance
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with the guidelines of the EANM.
Results
The investigation of the temporal distribution pattern of Lu-177-DOTATATE in the kidneys
revealed two different pharmacokinetic phases, a fast phase with a mean effective half-life of 25.8
± 12.0 min and a slow phase with a mean effective half-life of 63.9 ± 17.6 h. By the reduction of
the time points to the last four whole-body measurements and the assessment with the reduced
data model based on the mono-exponential function, an unacceptable dose underestimation of
12.4 ± 9.2 % compared to the full data model was observed. On the other hand, only a minor
deviation from the full data model and thus adequate dose estimation was found by applying
the reduced data model to only the latest three days, hence omitting the measurement at 1 h
post injection which contained a significant interference by the fast pharmacokinetic phase.
The established quantitative 3-D SPECT technique presented a sufficient recovery of known
activity in medium size spherical objects with more than 30 mm diameter (approx. 80 % and
above), although a significant underestimation of activity was observed in smaller spheres. With
this 3-D dosimetry an estimated dose of 2.2 ± 0.6 Gy for the kidneys (0.6 Gy/GBq), 0.4 ±
0.2 Gy for the liver (0.1 Gy/GBq) and 0.4 ± 0.1 Gy for the spleen (0.1 Gy/GBq) could be
reported. The dose to the salivary glands, being assessed with 2-D dosimetry, was 5.1 ± 1.8 Gy
(1.4 Gy/GBq). By combining all available 2-D- and 3-D-dosimetric data the absorbed dose of
the bone marrow was estimated with 44 ± 19 mGy (0.012 Gy/GBq).
Conclusion
Kinetic analyses of the renal uptake revealed a fast and slow washout phase. Thereby, the slow
phase component was found to be responsible to cause the major fraction of the absorbed dose
(98.9 %). Although the fast phase did not contribute substantially to the estimated renal dose,
it had a high likelihood of interfering with the slow phase within the initial hours after injection.
The unexpected dose underestimation which was observed with dosimetry calculations relying
on these early time points, such as the reduced data model including the 1h measurement,
could finally be explained with this discovery. These underestimations could lead to an over
dosage of the therapy activity and thus to a critical radiation exposure to healthy tissue. By
omitting this influenced measurement point and the solely use of the last three data points in
the reduced data model, the dose delivering phase could be accurately displayed. With the
insights gained in this study we were therefore able to develop a dosimetry model and workflow
with increased robustness and higher confidence in the reported dose estimates, which at the
same time relied on fewer measurements and therefore provided a significant reduction of work
load for the staff and overall burden for the patients. This model was then applied in the dose
assessment of the new radiopharmaceutical Lu-177-PSMA to avoid the above reported temporal
interference effects. Furthermore we observed increased activity accumulations in the intestine
after 24 h, which superimposed with the renal activity in the planar image projections and
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would thus lead to a falsified determination of activity for this risk organ in 2-D dosimetry.
To avoid this spatial interference, the quantitative 3-D SPECT method was established in the
clinic and optimized for imaging with Lu-177. The results of the final dosimetry calculations
for Lu-177-PSMA indicate a high tumor dose while low dose on healthy tissue was observed.
Therefore, an increased therapeutic activity could be recommended in order to maximize the
therapeutic effect.
x
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Zusammenfassung
Ziel
In der gezielten Radio Liganden Therapie ist die Erhebung dosimetrischer Daten zur Entwick-
lung angemessener und effektiver Therapieansätze unerlässlich. Ziel ist hierbei, die Strahlendosis
für den Tumor und somit den therapeutischen Effekt zu maximieren und gleichzeitig eine
möglichst geringe Strahlenbelastung für das gesunde Gewebe zu gewährleisten. Dazu werden
nach Gabe des Therapeutikums mehrere Aufnahmen mit einer Szintillationskamera angefertigt,
anhand derer die Kinetik und die quantitativ exakte Verteilung des Radiopharmazeutikums im
Körper bestimmt werden. In dieser Arbeit wurde zur Verbesserung der bestehenden Dosimetrie
Konzepte die Kinetik von Lu-177-DOTATATE, einem Radiopharmazeutikum für die Behandlung
von Patienten mit neuroendokrinen Tumoren, eingehend untersucht. Zusätzlich wurden die aus
dieser Studie gewonnenen Erkenntnisse verwendet, um die erste bildbasierte Dosimetrie bei dem
neuen Wirkstoff Lu-177-PSMA, einem Radiopharmazeutikum zur Behandlung von Patienten mit
metastasiertem Prostatakarzinom, durchzuführen. Wegen störenden Bildüberlagerungseffekten
bei der bisher verwendeten 2-dimensionalen (2-D) planaren Projektionsmethode wurde des
Weiteren eine verbesserte quantitative 3-dimensionale (3-D) SPECT Technik etabliert und für
die Dosisbestimmung optimiert.
Methoden
Die Charakterisierung der Dynamik von Lu-177-DOTATATE wurde mittels planaren Ganzkör-
perprojektionen von 105 Patienten zu den Zeitpunkten 1, 24, 48 und 72 h nach Injektion
durchgeführt. Zusätzlich wurde die erste Stunde nach Infusionsstart des Therapeutikums in
12 Zeitfenstern mit einer Dauer von jeweils 5 Minuten gemessen. Für die Nieren, die ein
Risikoorgan bei dieser Therapie darstellen, wurde dafür ein optimales 3-Phasen-Dosismodell
aufgestellt, das eine lineare Anstiegs-Phase bis zum Maximum der Anreicherung und einen
anschließenden 2-phasigen Abfall mittels Bi-exponential-Funktion beinhaltet. Dieses auf allen
verfügbaren Daten basierende optimale Modell diente als Grundlage für den Vergleich mit
vereinfachten Modellfunktionen, die auf eine reduzierte Datenmenge – die vier (1, 24, 48 und
72h nach Injektion) oder nur die letzten drei Ganzkörperaufnahmen - zur Dosisabschätzung
angewendet wurden.
Um eine ausreichend akkurate Dosimetrie des neuen Radio-Therapeutikums Lu-177-PSMA
zu ermöglichen wurden vorab Methoden untersucht, die die in planaren Bildprojektionen
auftretenden Aktivitätsüberlagerungen kompensieren oder vermeiden. Der vielversprechendste
Ansatz war dabei die Verwendung der quantitativen 3-D SPECT Technik, bei der Korrek-
turmaßnahmen für die Abschwächung der Photonenintensität, für die Streuung der Photonen
durch elektromagnetische Wechselwirkung und für die Unschärfe des Detektors in Abhängigkeit
vom Abstand implementiert werden mussten. Abschließend wurde für diese Methode ein
Kamera-spezifischer Kalibrationsfaktor bestimmt. Die quantitative 3-D SPECT wurde an-
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schließend mithilfe eines Kugelphantoms bezüglich ihrer Fähigkeit zur exakten Abbildung
bekannter Aktivitätskonzentrationen evaluiert und im Folgenden für die Rekonstruktion der 3-D
Patientenbilder angewendet. Bei der Organ- und Tumordosisbestimmung von Lu-177-PSMA
wurden bei fünf Patienten, die jeweils zwei Therapiezyklen durchliefen, 2-D Ganzkörperaufnah-
men und 3-D SPECT/CT Aufnahmen an den Zeitpunkten 1, 24, 48 und 72 h nach Injektion
durchgeführt. Zusätzlich wurden nach den Richtlinien der EANM für die Bestimmungen der
Knochenmarksdosen Blutproben der Patienten abgenommen.
Ergebnisse
Bei der Untersuchung des zeitlichen Verlaufs des Radiopharmakons Lu-177-DOTATATE in der
Niere konnten zwei unterschiedliche abfallende Phasen beobachtet werden: Eine schnelle Phase
mit einer mittleren effektiven Halbwertszeit von 25,8 ± 12,0 min und eine darauf folgende
langsame Phase mit 63,9 ± 17,6 h. Bei der Reduktion der Zeitpunkte auf die letzten vier
Ganzkörpermessungen und einer Modellierung mit einer mono-exponentiellen Funktion wurde
eine inakzeptable mittlere Dosisunterschätzung von 12,4 ± 9,2 % gegenüber dem Referenz-
modell festgestellt. Nur eine geringe Abweichung vom Referenzmodell wurde hingegen bei der
Verwendung des vereinfachten Modells unter zusätzlichem Auslassen des ersten Messtages und
ausschließlichem Fitten an die letzten drei Tage gefunden. Mit diesem Dosimetrie-Modell und
Protokoll konnte somit eine robuste und ausreichend genaue Dosisabschätzung gewährleistet
werden, und zudem durch die Reduktion der geforderten Messungen eine erhebliche Reduktion
des Arbeitsaufwandes für das Personal und der Belastung für den Patienten ermöglicht werden.
Die implementierte und optimierte 3-D SPECT Technik erlaubte die Abbildung der Aktivitäts-
konzentration in mittelgroßen Sphären mit mehr als 30 mm Durchmesser mit einer Genauigkeit
von 80 % und mehr, jedoch wurde eine deutliche Unterschätzung kleinerer Objekte beobachtet.
Die damit durchgeführte 3-D Dosimetrie zeigte eine Dosisabschätzung von 2,2 ± 0,6 Gy für
die Nieren (0,6 Gy/GBq), 0,4 ± 0,2 Gy für die Leber (0,1 Gy/GBq) und 0,4 ± 0,1 Gy für die
Milz (0,1 Gy/GBq). Für die Speicheldrüsen wurde eine Dosis von 5,1 ± 1,8 Gy mittels 2-D
Dosimetrie ermittelt (1,4 Gy/GBq). Die geschätzte absorbierte Dosis auf das Knochenmark war
44 ± 19 mGy (0,012 Gy/GBq).
Schlussfolgerung
Durch die kinetischen Analysen der Nierendynamik konnten schnelle und langsame Abkling-
phasen des Radiopharmakons gezeigt werden. Dabei wurde festgestellt, dass der für die
Dosis hauptverantwortliche Anteil (98,9 %) von der langsamen Phase ausgeht. Obwohl die
schnelle Phase nur einen geringen Anteil an der absorbierten Dosis ausmacht, besteht eine hohe
Wahrscheinlichkeit, dass sich diese in den ersten Stunden mit der langsamen Phase überlagert.
Die unerwartete Dosisunterschätzung, die in dem reduzierten Datenmodel unter Verwendung der
frühen Messung nach einer Stunde auftritt, konnte mit dieser Entdeckung erklärt werden. Diese
Unterschätzung könnte bei der weiteren Therapieplanung zu einer Überdosierung der Thera-
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pieaktivität und damit zu einer kritischen Strahlenbelastung des gesunden Gewebes führen. Mit
Auslassen dieser beeinflussten Messpunkte und der Verwendung der letzten drei Datenpunkte
konnte die dosiserzeugende Dynamik hingegen gut abgebildet werden. Mit den Erkenntnissen,
die in dieser Studie gewonnen wurden, konnten ein Dosimetrie-Modell und ein Messprotokoll
entwickelt werden, mit denen eine fundierte und verlässliche Schätzung der Dosis möglich ist.
Gleichzeitig verringern sich aufgrund der reduzierten Messungen der Arbeitsaufwand für das
Personal und vor allem die Belastung für die Patienten. Dieses Model wurde dann bei der
Dosisbestimmung des neuen Radiopharmazeutikums Lu-177-PSMA angewendet, um die oben
genannten zeitlichen Überlagerungseffekte zu vermeiden. Des Weiteren wurde nach 24 h eine
vermehrte Aktivitätsanreicherung im Darm festgestellt, die sich in planaren Bildprojektionen
mit der Nierenaktivität überlagert und somit zu einer verfälschten Aktivitätsbestimmung für
dieses Risikoorgan führen würde. Um diesen Überlagerungseffekt zu vermeiden, wurde die
quantitative 3-D SPECT Methode in der Klinik etabliert und für die Bildgebung mit Lu-177
optimiert. Die Ergebnisse der Dosimetrie-Berechnungen für Lu-177-PSMA weisen auf eine hohe
Tumordosis bei gleichzeitiger niedriger Dosis auf das gesunde Gewebe hin. Dadurch konnte eine
höhere Therapieaktivität empfohlen werden, um den therapeutischen Effekt zu maximieren.
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Nomenclature
NET Neuroendocrine tumor
PRRT Peptide receptor radionuclide therapy
2-D 2-dimensional
3-D 3-dimensional
CT Computed tomography
DOTATATE [DOTA0Tyr3]octreotate
DOTATOC [DOTA0Tyr3]octreotide
HCT Haematocrit
LOR Line of response
MAPE Mean absolute percentage error
MIRD Medical internal radiation dose
MRI Magnetic resonance imaging
p.i. Post injection
PET Positron emission tomography
PMT Photomultiplier tube
PSF Point spread function
PSMA Prostate specific membrane antigen
PVE Partial-volume effect
RC Recovery coefficient
RM Red marrow
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RMBLR Red marrow-to-blood ratio
RMECFF Red marrow extracellular fluid fraction
RoB Remainder of the body
ROI Region of interest
SPECT Single photon emission computed tomography
TAC Time-activity curve
VOI Volume of interest
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Chapter 1
Introduction
1.1 Targeted radiotherapies
Cancer is still one of the most lethal diseases worldwide. In 2012 14.1 million new cases and
8.2 million deaths were reported [23]. Especially the metastasis of cancerous tumor cells causes
an impairment of the health and difficulties in the treatment. In nuclear medicine the targeted
radiotherapy is a promising tool for the treatment of patients with metastasized tumors. For this
therapy, special characteristics of the tumor cells are utilized, for example the binding of anti-
bodies to prostate specific membrane antigen (PSMA) in the treatment of metastasized prostate
cancer [28], or the binding of somatostatin to its receptor on neuroendocrine tumors (NET)[45].
As an example for the treatment of NET, a synthetic somatostatin analogue coupled with a ra-
dioactive isotope is injected intravenously to bind to the tumor and irradiate the cancerous cells.
The most commonly used compounds for this peptide receptor radionuclide therapy (PRRT) of
NETs are octreotide and octreotate which are chemically coupled with the chelate [DOTA0Tyr3]
to DOTATOC and DOTATATE . The DOTA chelator enables the binding with a radioactive iso-
tope to create a tumor specific radiopharmaceutical, the so called tracer. Therefore, it is possible
to couple 68Ga, a positron (β+) emitter, used in the positron emission tomography (PET), to the
DOTA chelator for diagnostic examinations or to couple 177Lu, a more aggressive (β – )-emitting
radioactive isotope, to the radiopharmaceutical for the irradiation of the tumor cells [5]. Usually
several therapy cycles with intermediate follow-up examinations are performed for the treatment
of one patient [37][64]. An example image of a patient’s 68Ga-DOTATATE PET image before
and after the treatment with 177Lu-DOTATATE with a positive therapy response can be seen in
figure 1.1.
177Lu thereby proved to be a convenient isotope for the treatment because of the suitable half-
life of 6.6 days for constant irradiation of the tumor over a longer period of time, in contrast to
PET tracers whose half-lives are usually in the magnitude of hours. Also the β – energy with a
maximum of 0.5 MeV is favorable. The latter lead to a maximal distance in tissue of approx. 2
1
2
(a) 68Ga-PET image of a NET patient before
therapy
(b) 68Ga-PET image of a NET patient after
therapy
Figure 1.1: PET images of a patient with a hepatic metastatic neuroendocrine tumor of the
pancreas, before (left) and after (right) two cycles of 177Lu-DOTATATE therapy
mm which is desirable to target small tumor metastasis and preserve the healthy organs. Another
benefit of 177Lu are the additional γ-rays in the decay series with the major peaks at 113 keV
and 208 keV [6]. These enable scintigraphic planar images or three dimensional single photon
emission computed tomography (SPECT) images within the therapy cycles.
1.2 Dosimetry of radioligand therapies
1.2.1 Organ dosimetry
During the treatment of radioligand therapies not only the cancerous cells but also healthy
organs are irradiated by the radioisotope. Therefore dosimetric calculations, especially for the
risk organs, have to be performed to spare healthy organs while maximizing the tumor dose.
In nuclear medicine, the Committee of Medical Internal Radiation Dose (MIRD) suggested a
formalism for the calculation of the absorbed dose (eqn. 1.1)[41]:
DrT =
∑
rS
ÃrS · S(rT ← rS). (1.1)
Due to this formalism the mean dose D [Gy] for a target region rT is the sum of the dose
contributions from all source regions rS . Thereby the absorbed dose contribution from one
source region is calculated by the product of the accumulated activity ÃrS [Bq· s] and the source
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to target specific S-value [Gy/(Bq · s)]. The accumulated activity is the total number of all
nuclear disintegrations in one source region over time which is determined by the integral of the
time-activity curve (TAC) ArS (t) (1.2):
ÃrS =
∫ ∞
0
ArS (t)dt. (1.2)
In this therapy every patient has different tracer kinetics and the TACs have to be specified
individually for all organs and patients. Thereby exponential functions turned out to be feasible
TAC-models for the most organs and tumors.
After the determination of all disintegrations in one region, the energy deposition in the regions
or volumes of interest (ROI, VOI) is calculated by the S-value. This S-value, sometimes also
referred as dose conversion factor, is derived from Monte Carlo simulations of software phantoms
for each radionuclide and provides information about the absorbed energy fractions φ from a
certain source region rS to a target region rT with the mass M [kg]. The calculation of the
S-values is performed by
S(rT ← rS) =
∑
iEiφi(rT ← rS , Ei)
M(rT )
(1.3)
with the energy E [J] transmitted at each disintegration. The S-values for the most common
nuclides and major source organs are published in scientific journals [55][22][58], or in the online
retrievable RADAR database [59].
Patient individual scaling
A drawback of the MIRD S-value method is that patient individual characteristics are not in-
cluded. The patient size and the mass of the organs sometimes differ significantly from the Monte
Carlo phantoms. To regain more patient individual dose calculations, Williams et al. suggested
correction factors for the dose estimates for internal β− emitters [62]. Thereby the S-value of
the phantom is scaled according to equation 1.4,
S(patient) = S(MIRD) · m(MIRD)
m(patient)
, (1.4)
with the phantom and patient mass to obtain the individual patient S-value. Nevertheless for a
more specific dose calculation direct Monte Carlo simulations or dose kernel convolution methods
should be considered [31].
1.2.2 Bone marrow dosimetry
The irradiation of the red marrow (RM) is a special case in the dosimetry of radioligand therapies.
According to the guidelines of the European association of nuclear medicine (EANM)[33], the
RM-dose can be described as the dose fractions from the bone marrow self-dose (DRM←RM ),
the cross irradiation of the major source organs (DRM←Organs) and the remainder of the body
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(DRM←RoB)(eqn. 1.5), whereby the last two can be obtained from therapy images:
DRM = DRM←RM +
∑
rS
DRM←Organs +DRM←RoB . (1.5)
The bone marrow self-dose can be assessed by the activity concentration in blood with the
method suggested by Sgouros (eqn. 1.6) [52]:
DRM←RM = ˜[A]blood ·
RMECFF (= 0, 19)
1−HCT︸ ︷︷ ︸
RMBLR
·mRM,phantom · SRM←RM,phantom. (1.6)
For this purpose, blood samples of the patient at different therapy stages have to be collected
and the contained activity concentration measured. After obtaining the area under the
curve of the activity concentration, the red marrow dose can be calculated by the product
of this accumulated activity concentration ( ˜[A]blood), the mass (mRM,phantom), the S-value
(SRM←RM,phantom) and the red marrow-to-blood ratio (RMBLR). The RMBLR is composed
of the red marrow extracellular fluid fraction (RMECFF), which is assumed equal 0.19 and the
patient’s haematocrit (HCT) [52].
1.3 Imaging in nuclear medicine
The main purpose of imaging modalities in nuclear medicine is to investigate functional processes
of cells and organs in vivo with the help of concentration distributions of radioactive tracers.
The main tomographs in nuclear medicine, the PET and the SPECT, may be coupled to a
computed tomography (CT) (PET/CT, SPECT/CT) or recently also to a magnetic resonance
imaging (MRI) tomograph (PET/MRI) into a multimodal imaging device to have the advantage
of the structural and functional information in one examination [9][10][27][46]. These devices are
suitable to determine the time activity curves ArS (t) needed for dosimetry calculations (cf. eqn.
1.2).
1.3.1 Planar gamma camera images
A gamma camera, also called scintillation- or Anger camera, consists of one or more (usually
two) detector heads, which are capable to detect γ-photons. Thereby, a γ-ray could interact
and excite the detector’s crystal, which is usually a sodium-iodine crystal doted with Thallium
(NaI(Tl)). As a consequence, during relaxation of the excited crystal, it scintillates in the
visible light range. This light signal is then converted and amplified into an electrical signal
by a grid of photomultiplier tubes (PMT). A following signal processing electronics allows a
spatial information of each incident by performing a center of mass calculation amongst the
PMT-signals. Moreover, energy information of the detected photon is obtained by the sum over
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Figure 1.2: Two cropped pieces from a low energy (left) and an high energy collimator (right)
the signals of all PMTs [1].
Only γ-ray photons with a known input direction onto the detector are suitable to assemble
an image. Therefore, the impinging photon angle is limited by a collimator in front of the
scintillation crystal. A collimator is usually structured with several layers of lead which are
joint together to a honey-comb structure with holes for the photons to pass. The diameter and
length of the holes determines the possible resolution of the system, whereas the thickness of the
septa between the holes and the length of the collimator defines the applicable photon energy.
In figure 1.2 two parts of different collimators are presented. The collimators used in this work
are exclusively medium energy parallel hole collimators, suitable for the γ energy of 177Lu.
By positioning the detector heads over the desired anatomical region, a planar 2-dimensional
(2-D) projection of the activity distribution of the patient can be measured. Alternatively a
constant motion of the camera bed can cover a wider region up to whole-body planar images.
Thereby the usage of two or more camera heads allows the simultaneous measurement of different
angles. Another possibility is the division of one measurement into smaller time frames. Thereby
temporal information of the activity accumulation can be obtained.
1.3.2 Single Photon Emission Computed Tomography - SPECT
In principle the SPECT camera consists of the same detectors and collimators as the γ-camera
with the addition of a rotatable gantry which enables the motion of the detectors around the
patient. An example of a two head SPECT camera is shown in 1.3. In a SPECT measurement
the detector rotates in angular steps around the long side of the patient and records multiple
projections. These together with computed image reconstructions generate 3-dimensional (3-D)
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Figure 1.3: Image of a Siemens Symbia Intevo T16 SPECT/CT during a rotation around the
camera table
images of the tracer distribution in the patient [48][53][34].
A major advantage of the γ- or SPECT camera is the variety of different radioactive isotopes
which can be measured. Besides isotopes with a γ component, even pure β− emitters like 90Y can
be recorded because of the Bremsstrahlung [2][61]. This enables the radiochemistry to produce
versatile tracers for diagnostic purposes and therapy monitoring.
1.3.3 Positron Emission Tomography - PET
The positron emission tomography system is based on a circular detector array with a gantry
bore diameter of 70 to 90 cm [60][36][7]. The structure of these detectors, with a crystal and
photomultipliers (or semiconductors) is similar to the γ-camera but in contrary does not require
collimators to determine the line of response (LOR).
For this imaging modality the proton-rich PET nuclides (X) with the atomic number (A) and
the nucleon number (Z) disintegrate by β+ decay under the emission of an electron neutrino
(νe) and a positron (e+) to the new element (Y) by transforming one proton to a neutron (cf.
equation 1.7).
Z
AX −−→
Z
A−1Y + e
+ + νe (1.7)
The positron loses its kinetic energy through interaction with matter and combines with an elec-
tron situated in the environment after few micro- to millimeters. It annihilates to two equivalent
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photons flying in almost opposite directions. Due to the conservation of the positron’s momen-
tum a small deviation from 180 degree might occur. Both photons, each with an energy of
511 keV because of the mass-energy equivalence, then arrive nearly simultaneously within a few
nanoseconds at opposing detectors. This coincidence event defines the line of response (LOR)
from which the tracer distribution can be reconstructed with similar image reconstruction tech-
niques as utilized in SPECT. This electronic collimation does not require physical collimators
and therefore leads to higher sensitivity and better resolution compared to SPECT. Furthermore
if a PET isotope can be coupled to a therapy compound, this image technology is favorable for
pre-therapy examinations and follow-up monitoring.
1.4 Image degrading factors and calibration
In a variety of nuclear medicine image analysis the absolute quantitative concentration needs to be
assessed. Especially for dosimetry an exact activity quantification is needed. Therefore correction
methods have to be applied to compensate for several image degrading factors, followed by camera
calibration. In the following paragraph, the main image errors are introduced qualitatively. For
further descriptions of these effects the reference books of Bailey et al. and Zaidi et al. are
recommended [3][47].
1.4.1 Photon scattering
Due to the Compton effect the γ-photons are scattered in matter and consequently the detector
could measure events with a wrongly assumed origin. Thereby the initial wavelength λ changes
to λ′ after the scattering of the angle Θ (eqn. 1.8), with the constants me for the electron rest
mass, c for the speed of light and h for the Planck constant.
λ′ − λ = h
mec
(1− cosΘ) (1.8)
Especially scattered photons from higher γ-ray emissions into the energy acquisition window are
problematic. As a consequence, this leads to increased noise and overestimation of counts in the
activity determination.
1.4.2 Photon flux attenuation
Another image degrading effect is photon flux attenuation described by the Beer-Lambert law
(eqn. 1.9). From an emitted initial intensity I0 a fraction of the photons is absorbed by the
photo effect or scattered outside the LOR. In dependence of the mass attenuation coefficient µ
and the distance x in matter, only a reduced intensity I(x) is measured:
I(x) = I0e
−
∫
µ(x) dx. (1.9)
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Figure 1.4: Scheme of the distance dependent detector blur. Left: The photons emitted by a
point source near the collimator surface only pass through one hole which results in a sharp
signal. Right: The photons of a point source further away from the collimator surface are within
the acceptance angle of adjacent holes. Consequently the signal of the point source is blurred.
The image was provided by courtesy of Dr. Boening
Therefore the measured counts should be upwardly corrected, based on the covered path and the
accumulated attenuation coefficient to not underestimate the measured activity.
1.4.3 Distance-dependent image blur in SPECT
In nuclear medicine the resolution of a camera system is the ability to distinguish separated
sources of radioactivity. This resolution is dependent of the spatial position of the source. Al-
though all nuclear imaging methods suffer from effects which degrade the spatial resolution, here
only the distance-dependent detector blurring in SPECT measurements is illustrated in figure
1.4, because of the higher relevance of SPECT in this work.
The radiation of a point-source near the detector only passes through a few, or in this example
one collimator hole onto the scintillation crystal and generates a sharp signal, which could be
differentiated from the next source. If the point-source is farther away, the γ-rays are also in the
acceptance angle of the aperture of the next collimator holes and the resulting signal is broadened
by this effect which impairs the resolution.
1.4.4 Dead time
Besides the already introduced spatial image degradations, also the temporal count rate of the
detectors are limited and contribute to a decline of the image quality and absolute number of
measured counts. For SPECT cameras this effect appears at high activity concentrations and
thus at high count rates approximately over 40 kilo counts per second [63]. After a true radiation
event each detector system needs a certain recovery time before the next pulse can be counted.
All photons arriving the detector during this dead time aren’t processed and are lost for the
9
Figure 1.5: Graph of a dead time measured at the Siemens Inveon microPET system. The
purple line represents the estimated cps signal for the corresponding activity without dead time,
whereas the green curve, plotted from measurement results, depicts the reduced count rate in
dependency on the increased activity.
counting statistics.
Figure 1.5, measured with a Siemens Inveon microPET system illustrates this effect. While the
estimated real count rate increases linearly (purple), the slope of the count-signal for the true
coincidences decreases.
1.4.5 Partial-volume effect and spill-over
These two effects arise by the finite sampling and spatial resolution of the imaging system [56].
Because the sampling of the voxel matrix (3-D image array of volumetric pixels) often insuffi-
ciently maps the contours of the tracer distribution, voxels often include different tissue types.
Consequently such a voxel contains the fractionated activity signal of all underlying tissues. This
partial-volume effect (PVE) blurs and therefore reduces the activity signal at the edges of tracer
distributions. The other effect, the spill-over, occurs because of the limited resolution of the
system. As a result, the signal of a small source is blurred over a larger area, over the edges
of its actual border. Moreover the maximal intensity of the activity signal decreases with the
broadening. In case of adjacent source regions the activity signal spills in and out from each
region which could also create a distorted activity estimation. Both effects are often grouped
together under the term PVE.
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1.4.6 Calibration
Before a quantitative image is obtained, a calibration factor C [Bq/cps] for the conversion of the
measured cps to activity concentration [Bq/ml] for each voxel j must be applied by eqn. 1.10.
qj =
xj
T · V
· C (1.10)
This factor is derived from a measurement with the voxel count rate xj , a known acquisition
time T, voxel volume V and activity concentration for each voxel qj . Together with the above
mentioned correction factors thereby a quantitative emission image can be obtained.
1.5 Objectives of this thesis
The aim of this thesis was the investigation and improvement of dosimetry concepts in the image
based dosimetry for radioligand therapies using the radionuclide 177Lu.
The first objective was to precisely characterize the time-activity curves of the radiopharma-
ceutical 177Lu-DOTATATE in the kidneys, which are the major risk organs in this therapy. A
robust and feasible model had to be derived for accurate dosimetry based on only few imaging
time points, which is the situation in clinical routine.
The second objective was to perform the first image based dosimetric calculations for 177Lu-
DKFZ-PSMA-617, a new compound for the radionuclide therapy of prostate cancer. Therefore
the modeling of TACs for this unknown tracer dynamic was supported by the findings of the
first publication. Furthermore, a modification of the image analysis compared to the previous
publication was necessary, since, in addition to the temporal interference, a spatial interference
at the kidney region was observed. The latter could be addressed to activity accumulations
which superpositioned in the measured planar projection data. The aim of this second study
was to establish and utilize 3-D imaging techniques, which are superior to 2-D projection-based
techniques for the purpose of separation and delineation of multiple tracer accumulations in an
anatomical area.
Chapter 2
Studies
2.1 Preliminary studies for investigation of models with
temporal interference
The following section is based on the work Delker et al. 2013 in Nuklearmedizin and Delker
et al. 2014 in European journal of nuclear medicine and molecular imaging [16][15].
Besides the specific binding to neuroendocrine tumors during the PRRT with 177Lu-DOTATATE,
healthy tissue suffers from tracer accumulation and thus an unwanted irradiation. Especially the
kidneys are organs at risk. To estimate the absorbed dose in the kidneys subsequent measure-
ments have to be performed after therapy. Unfortunately the medical condition of these patients
is often considerably impaired. Therefore the acquisition of a large number of time points is not
appropriate and a reduced number of measurements has to be considered as basis for dosimetric
calculations. For this purpose the clinically established full-data model, being comprised of ac-
quisitions at days 1 (∼ 1 h), 2 (∼ 24 h), 3 (∼ 48 h) and 4 (∼ 72 h) after injection, was considered
as baseline and compared to reduced-data models in which one of these datapoints was omitted.
Then the mean absolute percentage error (MAPE) and the Spearman’s rank correlation coeffi-
cient (Rho) were calculated from the difference in the estimated absorbed dose. Furthermore,
computer simulations of the dose calculation based on the reduced data models were performed
to determine the expected deviation from the baseline.
Dosimetric planar image data of 10 patients were acquired on a Siemens E.Cam (Siemens Medical
Solutions, Erlangen, Germany) in anterior and posterior projections. Each image was corrected
for scatter and attenuation with the triple energy window method and the conjugate view method,
respectively [35][24]. Finally images were calibrated using the calculated net activity known for
the first time point. The following absorbed dose estimation was then performed according to
the MIRD concept with individual scaling for patient mass according to equation 1.4.
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Figure 2.1: Comparison of the dose estimated from planar measurements using all 4 datapoints
(1234, horizontal axes) to the case with one time point being omitted (vertical axes). The
bisecting lines (dashed line) the linear regression (red line) and the Spearman’s Rho values are
displayed in each graph.
For the simulations the mean effective half-life and the mean initial activity of the 10 patients
were used as a starting point to generate datapoints from a mono-exponential model similar to
those chosen in therapy. Additionally, a random noise was sampled from a normal distribution
(ND) with a standard deviation σ varied between 5 % and 30 % in 5 %-step intervals (eqn. 2.1):
ND(σ) = σ · 2
√
2ln2 with σ = 5, ..., 30%. (2.1)
Afterwards, alternately one of the datapoints was omitted and the remaining points were fitted
to a mono-exponential function to calculate the absorbed dose of these reduced data models.
In analogy to the patient experiment the resulting dose was compared to the baseline and the
MAPE was calculated from 1000 repetitions. This procedure was repeated for an effective half-
life range between 1.3 to 3.3 days -with regard to the mean effective half-life of 50.4 h observed
in the patient experiment- in steps of 9.6 h.
Comparing the effect of the reduced data models in patient measurements (figure 2.1), only
a small deviation and a very strong correlation was observed for the planar measurement 1,
3 and 4 (134) (figure 2.1, left), with a MAPE of 1.3 % and the Spearman’s Rho of 0.99 and
the measurement days (124) with a MAPE of 3.1 % and a Rho of 0.98 (figure 2.1, middle).
By omitting the last measurement (123) an elevated MAPE of 12.6 % and a Rho of 0.92 was
determined (figure 2.1, right). No special investigation of the error from the omission the first
whole-body measurement (234) compared to the baseline was performed, since its importance to
calibrate the planar images.
The simulation of the deviations of the dose estimates from the reduced data models to the
baseline resulted in figure 2.2. The surface plots show the mean deviation in dependency of the
effective half-life on the x-axis and the relative image error σ (cf. eqn. 2.1) on the y-axis for each
case. In contrast to the patient experiment, the configuration without the initial measurement
at 1 h p.i. was also simulated (234).
Taking into consideration the image errors, which were reported by Derajawa et al. to be up
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Figure 2.2: Mean deviation [%] of the simulated measurement setup to the baseline (1234) for
(123), (234), (134) and (124) each with alternating effective half-life [d] and relative error in the
images [%].
to 20 % [21], and the mean effective half-life from the patients of 2.1 d, a MAPE of 3.4 % for
simulation (134) and 4.7 % for simulation (124) was calculated. By omitting the first (234) or
the last (123) datapoint the MAPE changed to 6.8 % and 6.9 % respectively.
These studies, which were also presented and discussed at the annual meeting of the European
Association of Nuclear Medicine (EANM 2013) and the meeting of the Deutsche Gesellschaft für
Nuklearmedizin (DGN 2014) [16][15], offered a good comprehension of the expected deviations if
one measurement was canceled due to patient discomfort. No remarkable deviation was stated
when omitting one of the middle time points as confirmed via the simulation results. In concor-
dance with Larsson et al. [40], the deviation increased when excluding the latest time point
(fig. 2.2, top left), since this affected the integration to infinity significantly in the calculation of
the accumulated activity. In contrast, the increased MAPE which was observed when omitting
the first measurement (cf. figure 2.2, top right) was unexpected. Therefore a study for the
investigation of this effect was designed, which concludes in the first publication of this thesis:
The Influence of Early Measurements Onto the Estimated Kidney Dose in [177Lu][DOTA0,Tyr3]
Octreotate Peptide Receptor Radiotherapy of Neuroendocrine Tumors [14].
2.2 Investigation of models with temporal interference
The following section is based on the publication Delker et al. 2015 in Molecular imaging
and biology and the work Delker et al. 2014 in European journal of nuclear medicine and
molecular imaging and Delker et al. 2015 in Nuklearmedizin [14][19][20].
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Figure 2.3: Posterior planar whole-body view approx. 1, 24, 48, 72 h (from left to right) after
administration of 177Lu-DOTATATE.
The aim of this work was to investigate the influence of early time point measurement in the renal
dose calculation by comparing the conventional mono-exponential model to an extended, but in
clinical routine unfeasible model and the impact onto the estimated kidney dose in dependence
of the measurement dates. Therefore, dynamic planar 1-bed recordings in 12 frames, each 5
min, were acquired in supplement to the conventional whole-body planar scintigraphy images at
approx. 1, 24, 48 and 72 h after administration of 177Lu-DOTATATE (see figure 2.3).
A three-phase model with a linear increase to the maximum within the initial minutes post
injection (p.i.) followed by a bi-exponential decline served as reference model for evaluating
accuracy of the dose estimates compared to the conventional mono-exponential model in 105
patients. The mean effective half-lives of the bi-exponential were 25.8 min ± 12.0 min for the
fast phase and 63.9 h ± 17.6 h for the slow phase. Then the optimal measurement date was
investigated by comparing the deviation to the baseline model of the fit to all four whole-body
measurements (4P-fit) or only to the last three (3P-fit). Although various functions were tested
by the statistical F-test, the mono-exponential was calculated to be the best suitable. In this
study we could show that the first whole-body planar measurement of the kidneys at 1 h has
a high probability of being interfered by a second phase which is very likely originating from
the remaining blood activity. Consequently the activity at this time is artificially increased,
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Figure 2.4: (a) TAC of the reference TrBi-exp model in green, fitted to the 12 dynamic planar
datapoints (filled circles) and the 4 whole-body images (open squares). The single phase fractions
of the bi-exponential are plotted in blue and red. (b) Expansion of the dashed rectangular in
(a) to visualize the first 6 h.
as illustrated in Figure 2.4. There the reference model TrBi-exp is plotted in green onto the
dynamic (filled squares) and whole-body (open squares) datapoints. Its two phases, the fast and
slow washout phase are depicted separately in blue and red. The first whole-body datapoint at
approx. 1.5 h is clearly elevated above the slow washout phase (figure 2.4b).
Different than expected this elevated datapoint doesn’t result in an increased absorbed dose when
using the mono-exponential 4P-fit but in a mean underestimation of 12.4 % ± 9,2 %, because of
a steeper descent of the exponential. This underestimation could lead to a higher administered
activity in the next cycle and thus to an overdosage. Whereas the 3P-fit, with the first elevated
whole-body excluded, only differs slightly from the reference model. In figure 2.5 these results
are summarized for all 105 kidneys.
In this work an underestimation of the dose estimate could be prevented by choosing the ap-
propriate model which is designed to be insensitive to a temporal interference of different phase
fractions. Moreover, also a reduction of the workload for patients and staff was achieved without
a major loss of accuracy.
2.3 Preliminary studies for investigation of spatial interfer-
ence
2.3.1 The effect of overlying extra renal activity on estimated renal
doses from planar scans
The following section is based on the work Delker et al. 2012 in European journal of nuclear
medicine and Delker et al. 2014 in Nuklearmedizin [18][17].
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Figure 2.5: Boxplot of the estimated dose calculated for TrBi-exp (left), the four datapoint
mono-exponential fit (middle) and the three datapoint mono-exponential fit (right). Outliers are
plotted individually (red).
In targeted radiotherapies an accurate and quantitative determination of the regional tracer
distribution in the patient is necessary to calculate the absorbed dose. As described before,
several imaging modalities are provided for this task in nuclear medicine. Particular planar
2-D gamma camera images are commonly used for therapy images because of their feasibility.
A drawback of this method are activity interferences from consecutive activity regions which
accumulate in the planar projection to an artificial higher distribution. To improve this
impairment a method of extrapolating the mean activity in an overlay-free part of an organ to
its whole volume was examined. Furthermore, the more complex 3-D SPECT technology was
used to compare and correlate the results of the methods.
To investigate the impact of the correction method onto the dose calculations, 13 patients were
measured with anterior and posterior planar images at 1, 24, 48, 72 h after administration of
177Lu-DOTATATE. Subsequently to each planar measurement a 3-D SPECT measurement was
acquired at the abdomen. The kidneys, as previously mentioned being one of the organs at risk
in this therapy, were examined because of a frequent overlapping of the liver activity distribution
onto the activity signal of the right kidney in planar projection data. To compensate for this
overlay two separate ROIs were drawn: One to assess the mean accumulation in the overlay
free area and the other to specify the organ size. Thereafter, the activity was extrapolated over
the entire organ to calculate the residence time (RT) as a surrogate for the absorbed dose. As
reference for an overlay free activity-signal the SPECT measurements were utilized. For an
objective comparison the Spearman’s ρ for correlation and the Mann-Whitney U-test with the
probability p for significance were performed [57] [43].
The results of this study which were presented at the EANM 2012 are shown in figure 2.6 [17].
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Figure 2.6: Residence times (RT) of the different methods with (bottom row) and without renal
overlay (top row)
In the absence of overlay a strong correlation was indicated for the classical planar (Spearman’s
ρ = 0.87) (fig. 2.6, left) and the extrapolated planar method (ρ = 0.91) (fig. 2.6, right) in
comparison to the SPECT. Also no significant difference was found with the Mann-Whitney U
test for the planar method (p = 0.27) with the average residence time of 1.55 ± 0.30 h and for
the extrapolated planar method (p = 0.14) with the RT of 1.56 ± 0.37 h, assuming a significance
level of 5 %. With overlay of the kidneys no correlation between SPECT and the planar method
was found (ρ = -0.37). Also the extrapolated planar method offered no substantial improvement
with a ρ of 0.30. The U-test indicated a significant difference between planar and SPECT (p =
0.0002) and extrapolated planar method and SPECT (p = 0.04). Only a small improvement for
the mean RT was achieved from 3.43 ± 2.44 h for planar to 1.65 ± 0.61 h with the extrapolated
planar method in comparison of 1.14 ± 0.37 h for SPECT.
Without extra renal activity the planar and the correction by extrapolation provided similar
results which indicates a general functionality of this method. However, no accordance was
found when activity overlay was present. Potentially this arises because of an elevated activity
signal next to the superimposed area which results in higher mean values. Because no accurate
activity distribution and therefore absorbed dose calculation could be performed if this spatial
activity interference is present, a substantial need for a reliable method for activity determination
was present. Therefore the focus was directed to the more complex but overlay independent
quantitative SPECT, as described in the following sections.
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2.4 3-D Dosimetry based on quantitative SPECT for a new
therapeutic compound
The following section is based on the publication Delker et al. 2015 in European journal of
nuclear medicine and molecular imaging and the work Delker et al. 2015 in European journal
of nuclear medicine and molecular imaging and Delker et al. 2015 in Journal of nuclear
medicine [13][12][11].
Prostate cancer, one of the most occurring tumors affecting men, tends to become highly ag-
gressive over time and causes the death of more than 250,000 people each year [42]. With the
radioligand 177Lu-DKFZ-PSMA-617 a promising new tool for the treatment was developed. To
determine the optimal treatment activity to achieve the best therapeutic effect with limited side
effects a dosimetry is mandatory. The aim of this study was to perform the first image-based
absorbed dose calculations for this new PSMA ligand. To accurately investigate the dose distri-
bution for this new therapeutic approach, we decided to utilize quantitative 3-D SPECT imaging.
Quantitative 3-D SPECT images offer a series of advantages over the 2-D planar scintigraphies.
Besides the possibility to distinguish between overlapping source distributions, this technique
also allows for voxelwise activity determination which enables the calculation of heterogeneous
dose maps with the help of convolution or Monte Carlo methods. For the quantification of the
SPECT, the image-degrading effects presented in chapter 1.4 have to be compensated. To correct
the image for the scattered photons the triple-energy window method, similar to Ichihara et al.
was utilized [35]. Because of the Compton energy shift in case of an inelastic scatter event (cf.
eqn. 1.8), the influence of the scattered photons on the main photopeak window can be offset by
acquiring additional adjacent energy windows (cf. figure 2.7). From these, the trapezoidal area
in the main photopeak, representing the interspersed photons, is estimated and subtracted by
the integral of the linear connection between the measured counts of the two scatter windows.
To compensate the attenuated photon signal described in chapter 1.4, the Hounsfield units of
a co-registered CT were converted into a map of linear attenuation coefficients (µ-map). A
difficulty in this process is the generation of energy-dependent µ-values for the narrow emission
energies of the radionuclides from the broad polychromatic X-ray spectrum. Hence the CT
system with the operating voltage of 130 kVpeak was characterized with the Gammex 467 tissue
characterization phantom (Gammex, Inc.) shown in the insert of figure 2.8. Then, because of
the known material composition of the phantom rods, conversion factors from the CT Hounsfield
units to linear attenuation coefficients could be derived for the desired energies. The µ-values
for the corresponding radionuclide energies of one mixture were obtained from the database of
the National Institute of Standards and Technology (NIST) [44], by summing up the weighted
atomic constituents i:
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Figure 2.7: Energy spectrum with photopeak (A and B) and scatter (C to F) windows transcribed
during a SPECT measurement with 177Lu. The scales are measured counts on the y-axis and
energy in keV on the x-axis.
µ
ρ
=
∑
i
wi(
µ
ρ
)i. (2.2)
As an example in figure 2.8 the bi-linear plots for the conversion of HU to the two main 177Lu
photopeak energies are plotted. At this point it should be noted, that both photopeaks were
acquired in the measurements of this work (also compare figure 2.7), but only the upper energy
peak at 208 keV was processed for image reconstruction. In general, the count statistics in
therapy images with 177Lu is sufficient, but if deemed necessary also the lower peak at 113 keV
could be additionally processed.
Finally, a model was included in the reconstruction algorithm to describe the distance dependent
detector response. Therefore a point source of 177Lu was measured at different distances of the
detector head, which was equipped with a medium energy collimator. The measured signal of
the point source was fitted to a gaussian function to derive a distant dependent model of the
point spread function (PSF). Consequently, with the PSF included in the system matrix of the
reconstruction and the distance from the detector, which is obtainable from the image header,
a resolution recovery could be achieved. In this work no dedicated corrections were applied for
deadtime, partial volume effects and spill-over. The applied image reconstruction was "a rotation-
based one-step-late penalized ordered subsets expectation maximization algorithm" [11]. In our
featured publication (Delker et al.) it is “described by equation [...][2.3],
xk+1j = x
k
j
1∑
i∈Sn aij + β
(
P (xkj )
) ∑
i∈Sn
aij
yi
(
∑
j aijx
k
j ) + si
(2.3)
where P (xkj ) denotes a quadratic filter operation onto voxel j using its 5 × 5 × 5 neighboring
voxels, and Sn is the subset of projections to be considered. A penalty weight factor β was of low
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Figure 2.8: Bi-linear conversion graph from CT Hounsfield units to linear attenuation coefficients
(per cm). The known phantom rod µ values were plotted to the measured CT Hounsfield units
for the main 177Lu photopeaks at 208 keV (red) and 113 keV (blue).The insert in the left upper
corner shows the CT image of the used Gammex 467 characterization phantom.
magnitude in order to slightly reduce the Gibbs artefacts without greatly sacrificing resolution.
According to [. . . ][eq. 2.3], the final image xk after iteration k contained the number of recon-
structed counts per voxel. Quantitative emission images, obtained as activity concentration per
unit volume (i.e. q in Becquerels per millilitre) in each voxel j, were then calculated ” with the
calibration factor C by equation 1.10 [11]. This factor was determined by a separate measurement
of a cylindric calibration phantom with known activity and yielded a C of 110,058 Bq/cps.
The effect of the presented image corrections with applied calibration factor are exemplified in
the NEMA-NM-2001 phantom measurement shown in figure 2.9. Therefore six spheres of inter-
nal diameters of 37 mm, 28 mm, 22 mm, 17 mm, 13 mm and 10 mm were filled with an activity
concentration of 75.6 kBq/mL of 177Lu-solution in water. Moreover an activity concentration
of 7.5 kBq/mL was mixed in the background, resulting in an foreground-to-background ratio of
approximately 10:1. In figure 2.9, the corrections applied for the reconstruction are abbreviated
with a for attenuation correction, s for scatter correction and b for distance dependent detector
blur. Here, the need for compensating the image degrading factors becomes apparent. Without
any corrections (a0s0b0), the recovery coefficient (RC) of the background was 26 % (cf. figure
2.10(b)). Moreover, high image noise, identifiable by the large error bar, was present. By ap-
plying the appropriate model for the distance detector blurring (a0s0b1), the noise is canceled
out and the edges of the spheres become more defined (cf. figure 2.9(b)). However the RC did
not change substantially, displayed by the blue bar in figure 2.10(b). If the scatter correction is
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(a) a0s0b0 (b) a0s0b1 (c) a0s1b1
(d) a1s0b1 (e) a1s1b1
Figure 2.9: Reconstructed images of a NEMA 2001 phantom with hot spheres and background
activity. The corrections performed are abbreviated with a for attenuation correction, s for
scatter correction and b for distance dependent detector blur, followed by the digit 1 if performed
and 0 if not, respectively.
performed in addition (a0s1b1), the overall signal is even reduced further because of the subtrac-
tion of the interspersed photons in the photopeak. The effect of the attenuation compensation
(a1s0b1) is illustrated by the significant increase of the RC, which even overcorrects the signal to
128%. Finally, by considering all correction factors (a1s1b1) the RC reaches 93 %. Apparently
the activity recovery of the spheres (figure 2.10(a)) with all corrections (a1s1b1) is below the
background RC. Moreover, it decreases with sphere size from 81 % for 37 mm diameter to a
disappearance in the background noise (approx. 12 %) for the smallest sphere with 10 mm. This
most likely originate of the inherent spatial resolution of the SPECT system and the absence of
compensation for partial volume effects.
Five patients were treated in two cycles with 3.7 GBq 177Lu DKFZ-PSMA-617. To estimate the
accumulated activity of the tumors and organs, planar and SPECT images were recorded at 1
h, 24 h, 48 h and 72 h post injection. Moreover, blood samples were collected for bone marrow
dosimetry.
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(a) Recovery coefficients of spheres (b) Recovery coefficient of background
Figure 2.10: Recovery coefficients (RC) calculated from the NEMA 2001 phantom images shown
in 2.9, with the same abbreviations. (a) RC calculated for each sphere size. (b) RC calculated
for the 784 mL background VOI. The different colors in both figures distinguish between the
correction methods applied.
Figure 2.11: a Dose model curves of activity concentrations in a representative patient in one
tumor metastasis (red), kidneys (cyan and dashed blue), spleen (orange) and liver (green). b
Activity concentration curves from the blood samples (red) and the whole-body (green) for
calculation of the bone marrow dose.
The time-activity curves for the organs and tumors were modeled with multiple distinct
phases due to the experiences and results of the previous work (cf. figure 2.11). After
approximately 24 h an increased uptake in the intestine was observed which superimposed the
kidneys in the planar scintigraphies (figure 2.12). Due to this spatial interference the overlay-free
quantitative 3-D SPECT images were utilized for the dosimetry calculations of the abdominal
organs (figure 2.13). The bone marrow was estimated from a combination of the blood sampling
method and image data, presented in section 1.2.2. Thereby the remainder of the body was
calculated by the accumulated activity from the whole-body planar images, minus the activity
of the organs and the blood. The estimated absorbed bone marrow dose was 12 mGy/GBq per
cycle.
Besides the tumor the highest absorbed dose estimates were observed in the kidneys (0.6
Gy/GBq) and the salivary glands (1.4 Gy/GBq), however both absorbed dose values are not
critical considering the administered activity of 3.7 GBq. Furthermore, the liver and the spleen
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Figure 2.12: Anterior planar whole-body images at (a) 1, (b) 24, (c) 48 and (d) 72 h.
Figure 2.13: Serial fused SPECT/CT coronal images at (a) 1, (b) 24, (c) 48 and (d) 72 h.
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received a considerably low dose of 0.1 Gy/GBq each. Consequently we recommended a more
aggressive treatment, starting with an administered activity of 6.0 GBq to optimally exploit the
absorbed tumor dose.
Chapter 3
Discussion
In this work, therapy images for dosimetry of 177Lu-labeled tracers were investigated for temporal
and spatial effects. In the first study, the multi-phase kinetic of the tracer 177Lu-DOTATATE
was investigated.
Although a single-phase mono-exponential model proved to be sufficient for dose estimations
with only small deviations of a few percent from the best model, we observed that this mono-
exponential model is highly sensitive to the appropriate selection of data to be fitted. By choosing
a set of inappropriate time points a mean underestimation of dose of 12.4 % ± 9.2 % was
noted. Assuming multiple therapy cycles, the danger of a substantial overexposure of the risk
organ is present. Due to the measurement of a large set of time points and the assessment of
the pharmacokinetics using multi-phase models, this effect could be addressed to the temporal
interference of fast and slow pharmacokinetic phases. Consequently, the assumed initial model
for the performed simulations of the preliminary studies in chapter 2.1 inadequately described
the true temporal activity distribution. By adapting and repeating the simulations, new surface
plots of the mean deviation were calculated (figure 3.1).
In this simulations a model for multiphase kinetics with linear increase and bi-exponential
washout was included to describe the baseline to which in analogy to the simulations of fig-
ure 2.2 the reduced whole-body setup was analyzed. Comparable to the results of the first
publication [14], the omission of the first measurement (d234) (figure 3.1, top right) causes only
a minor deviation to the baseline of approximately 1 %, assuming 48 h effective half-life and
an image error of 20 %. With the inclusion of the influenced first measurement (figure 3.1, top
left and bottom row) an increased deviation of 11 % for (d123) and 8 % for (d134) and (d124)
was observed. This simulation confirms the finding of the publication, that almost the entire
dose (98.9 %) is caused by the slow phase component and an accurate determination of the slow
phase could therefore be sufficient to characterize the dose. Hence, the fit to the datapoints of
the mono-exponential function were adapted with omission of the measurements at therapy day
to avoid the risk of temporal interference effects. This enabled an improved calculated absorbed
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Figure 3.1: Mean deviation of the simulated measurement setup to the adapted baseline with
linear increase to the maximum, followed by a bi-exponential function. In analogy to 2.1 the
effective half-life and the relative error in the images was altered.
dose with supplemental minimization of the work load for staff and patients.
In order to compensate spatial interference effects, which occur in planar therapy images, two
methods were investigated. At first, we studied a method of extrapolating an overlay free activity
region over the whole organ (cf. section 2.3). As a proof of principle, this method was tested
with overlay free kidneys and showed good correlations. But with overlay no significant improve-
ment could be achieved, potentially because of an elevated activity signal in the surrounding
of the superimposed area. Because these attempts have not been successful, quantitative 3-D
SPECT was established and optimized for the dose calculation in our department. Therefore a
phantom measurement was performed to evaluate this method. For the spheres with a volume
greater than 10 mL a recovery coefficient of approximately 80 % was determined, which is in
good accordance to a recent study of 177Lu SPECT quantification [49]. The decrease of the RCs
with sphere size "most likely arose from inherent spatial resolution, with signals uncorrected for
partial volume and spill-over effects" [11]. Because dosimetry is mostly performed to estimate
the dose to the larger risk organs, no special need to include these corrections was present. How-
ever, the tumor dose assessment is affected and the implementation of these corrections should
be considered. Moreover, no dead time correction was included in the SPECT workflow yet. In
the study of the new PSMA compound [11], a relatively low therapy activity of 3.7 GBq was
administered. Therefore, no substantial dead time error was expected. Furthermore, in this
study we observed an activity signal in the intestine which overlapped significantly with the
kidneys in planar scintigraphies (cf. figure 2.12). That made the application of SPECT-based
3-D dosimetry indispensable. With the choice of the appropriate model and the compensation
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Figure 3.2: Simulation geometry and total energy deposition of the FLUKA Monte Carlo code.
The CT body data was overlayed by the estimator results for total energy. Image taken from
[29].
of spatial interference effects due to the application of the 3-D SPECT imaging, first reliable
dose estimates could be determined for this new therapeutic compound. To avoid the fitting of
a one-phase model to a temporal interfered measurement of multiple phases, the first datapoint
was excluded from the fit but instead interpolated linearly (cf. fig. 2.11).
The calculated absorbed doses for 177Lu-PSMA with this model were 0.6 Gy/GBq for the
kidneys, 0.1 Gy/GBq for the liver and 0.1 Gy/GBq for the spleen. The kidneys, being the dose
limiting organ in a number of radionuclide therapies [8][38], received the highest dose amongst
the evaluated abdominal organs. Nevertheless the dose is comparable to the well established
177Lu-DOTATATE therapy, which was published previously [50]. With the help of the whole-
body planar scintigraphy, the mean absorbed dose to the salivary gland was determined to be 1.4
Gy/GBq. Nevertheless, no patient complained of xerostomia during the follow-up. Furthermore,
from external beam therapy a dose of 30 to 40 Gy was reported to be critical [26][32], which
was not reached in any patient during the treatment with 177Lu-DKFZ-PSMA-617. The bone
marrow, which is critical in other targeted radionuclide therapies [25][39][54][52], was estimated
to absorb a dose of 12 mGy/GBq. This is well below the critical level of 2 Gy [25]. Nevertheless,
the utilized model for bone marrow calculation did not take into account the high amount of
activity near or within the red marrow because of the variety of bone metastasis. Because no
critical organ dose was observed in the therapy of this new treatment option for patients with
metastasized castration resistant prostate cancer, a more aggressive treatment activity could be
suggested.
As emphasized in section 1.2, only minor corrections for patient individual scaling are performed
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(a) Map of accumulated activities
(b) FLUKA 3-D total absorbed dose
(c) FLUKA 3-D photon dose
Figure 3.3: Monte Carlo based 3-D patient study with 177Lu-PSMA. (a) Patient specific map of
accumulated activities. (b) Simulated 3-D dose map in [Gy]. (c) Photon dose contribution of
the dose. The images were taken from [29].
with the MIRD S-value dose estimation. For more patient specific calculations, the dose dis-
tribution in the true anatomical patient geometry would be desirable. In this matter, a brief
outlook of the preliminary results of direct Monte Carlo simulations and convolution methods
with dose point kernels is presented in the following paragraph.
The Monte Carlo simulation is regarded as the most precise and patient specific method to
calculate the absorbed dose [21]. To determine the energy deposition in the patient via MC,
the simulation geometry with the material composition is required, which was obtained by
the conversion of Hounsfield units as proposed by Schneider et al. [51]. Together with the
accumulated activity derived from the 3-D SPECT images, which served as source input map,
the energy deposition in the patient could be simulated as shown in figure 3.2 using the MC
code FLUKA [4]. As an example, figure 3.3 shows a PSMA patient simulated with FLUKA.
Furthermore, the MC simulation enables the possibility to investigate special characteristics
of the isotope, for example the contribution of the photon energy deposition to the absorbed
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Figure 3.4: 177Lu-specific S-value kernels simulated for 4.8 mm3 soft tissue voxels. The images
were taken from [29].
dose in figure 3.3(c), which causes approx. 1 % of the dose for 177Lu. A drawback of this
method is the time-consuming simulation process. An alternative to full MC calculations are
pre-calculated dose point kernels. These are simulated for representative tissue types such as a
kernel for soft-tissue depicted in figure 3.4. These kernels then can be scaled via the CT density
and convolved with the activity distribution to obtain the absorbed dose map. Especially in
regions where the majority of the energy deposition originate from photons, these methods
could improve the accuracy of the dose estimation.
As noted earlier, due to the high amount of activity near or in the bones, a higher absorbed dose
to the red marrow is expected. To assess the additional absorbed dose caused by these activities,
the latter introduced methods for 3-D dosimetry were applied. At the annual conference of the
EANM 2015 ([30]), we indicated a notably dose contribution from the metastasis to the bone
marrow of up to 41 % as calculated with MC simulations. Nevertheless the magnitude of the
total dose was still below the commonly applied constraints. Furthermore, no harmful influence
of other source regions onto the RM was detected.
With the studies and the related publications, which have been summarized in this thesis, some
of the major tasks of dosimetry calculation were addressed. It could be shown, that carefully
determined models which avoid temporal and spatial interference effects improve the calculation
of the absorbed dose and are even suitable to reduce the burden for patients and the work load
for the staff. Consequently, with these findings, an accurate dose risk assessment of the new
radiopharmaceutical for the treatment of metastasized castration resistant prostate cancer was
achieved. Furthermore, the models developed in this thesis serve as a robust input to even more
sophisticated approaches such as Monte Carlo simulations or dose kernel convolutions for voxel-
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wise investigation of the regional distribution of radiation exposure and dose assessment in well
established and innovative prospective radioligand therapies.
Chapter 4
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Abstract
Purpose: Multiple measurements have been required to estimate the radiation dose to the kidneys
resulting from [177Lu]DOTATATE therapy for neuroendocrine tumors. The aim of this study was to
investigate the influence of early time-point measurement in the renal dose calculation.
Procedures: Anterior/posterior whole-body planar scintigraphy images were acquired at approx.
1, 24, 48, and 72 h after administration of [177Lu]DOTATATE. Furthermore, we acquired planar
1-bed dynamic recordings in 12 frames (5 min each) during the first hour. We assessed kidney
exposure with a three-phase model consisting of a linear increase to the maximum within the
initial minutes p.i., followed a bi-exponential decline. This three-phase-model served as
reference for evaluating accuracy of dose estimates in 105 kidneys calculated by conventional
mono-exponential fitting of the final three and four whole-body images.
Results: Mean effective half-life times for the reference model were 25.8±12.0 min and 63.9
±17.6 h, predicting a mean renal dose of 5.7±2.1 Gy. The effective half-life time was 46.3±15.4 h
for the last four and 63.3±17.0 h for the last three data points. The mean start of the first whole-
body measurement was 1.2±0.1 h p.i. The ratio of fast to slow phases was 28.1±23.9 % at this
time point, which caused a mean absolute percentage dose deviation of 12.4 % for four data
points, compared to 3.1 % for three data points. At a mean time of 2.4 h p.i. (max 5.1 h), the ratio
of fast to slow phase declined below 5 %.
Conclusions: Kinetic analysis of renal uptake using dynamic planar scans from the first hour after
injection revealed a fast and a slow washout phase. Although the fast phase did not contribute
substantially to the estimated renal dose, it could influence planar measurements performed within
the first hours. We found that the presence of two clearance phases can hamper accurate dose
estimation based on a single-phasemodel, resulting in approximately 12.4% dose underestimation,
thus potentially resulting in overtreatment. In the absence of dynamic initial recordings, the first
dosimetry measurements should therefore be obtained later than 3–5 h after [177Lu]DOTATATE
injection. Omitting the early whole-body image reduced the dose estimation error to 3.1 %.
Key words: Neuroendocrine tumor, Lutetium 177, Kidney dose, Dosimetry, Peptide receptor
radionuclide therapy
Correspondence to: Guido Böning; e-mail: guido.boening@med.uni-
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Introduction and Aim
P eptide receptor radionuclide therapy (PRRT) withradiolabeled somatostatin analogues has emerged as a
well-established therapy option in the management of
patients with metastasized neuroendocrine tumors (NETs)
expressing somatostatin receptors, according to recently
established guidelines [1, 2]. Currently, the most commonly
used compounds are [90Y][DOTA0,Tyr3]octreotide
([90Y]DOTATOC) and [177Lu][DOTA0,Tyr3]octreotate
([177Lu] DOTATATE). Response to therapy is encouraging,
with progression free survival of 33 months and overall
survival rates up to 46 months [3, 4]. Although PRRT is well
tolerated in most NET patients, and severe complications are
rare, radiation toxicity remains a therapy-limiting factor.
Whereas hematoxicity is fortunately reversible in most
cases, the kidneys are particularly at risk for overexposure
[5, 6]. Cumulative dose values ranging from 23 to 29 Gy to
the kidneys are reported as acceptable, in the absence of
additional renal risk factors [7, 8].
PRRT with the beta- and gamma-emitting somatostatin
analogue [177Lu]DOTATATE is accompanied with fewer
side effects and yet equally successful therapy response rates
as compared to [90Y]DOTATOC [3]. Furthermore, Lu-177
lends itself better for performing image-based dosimetric
studies because of the gamma component, which allows
simultaneous scintigraphy marking the beta treatment.
Therapy is usually performed with standard doses of
7.4 GBq per cycle within four to six cycles [2]. Dose
escalation and optimal patient-specific treatment informed
by pre- and peri-therapeutic dosimetry findings, however,
might enable maximal radiation dose to the tumors.
In general, the radiation exposures of the tumor and also
the risk organs have to be monitored at intervals during the
therapy so that total doses in the regions of interest can be
calculated with some accuracy. A few well-selected time
points must serve to this end, sparing the expense and effort
entailed in collecting a prolonged series of measurements. In
this regard, Larsson et al. [9] emphasized the importance of
late time points for estimating radiation dose due to the long
physical half-life of Lu-177. We now aim of optimizing
clinical dosimetry with consideration of the influence of
early time points on the estimation of kidney dose using a
multi-phase kinetic model.
Material and Methods
Patients and Therapy
Patients with histologically proven well-differentiated metastatic
NETs with expression of somatostatin receptors and a Ki-67
proliferation marker under 20 % were treated in multiple cycles
with a default activity of 7.4 GBq [177Lu]DOTATATE per cycle.
Labelling of the precursor DOTATATE (ABX GmbH, Radeberg,
Germany) was performed according to the method described by
Breeman et al. [10] with slight modifications. The labelling with
n.c.a. Lu-177 (ITG GmbH, Garching, Germany) was performed
with 125 μg peptide precursor in acetate buffer (pH 4.7). The
radiochemical yield was greater than 95 % and the radiochemical
purity greater than 98 % in the final preparation. For kidney dose
estimation of one treatment cycle, we collected a sample of 64 (27
female, 37 male) consecutive patients (aged 62±12 years; range 22–
89 years). In some cases, more than one therapy cycle was used for
the data analysis, resulting in a total of 105 datasets. The
radiopharmaceutical was intravenously infused during 30 min at a
rate of 1.6 ml/min. For prophylaxis against kidney damage, the i.v.
administration of 1 l of an arginine and lysine solution (Pharmacy
of the University Hospital of Munich, Germany) was initiated
30 min prior to the administration of the therapeutic (rate
5.8 ml/min).
Acquisition
Prior to therapy, a diagnostic PET/CT scan (Biograph 64 TruePoint,
Siemens Medical Solutions) using [68Ga]DOTATATE had been
performed to locate the tumor metastasis and to quantify the maximum
standardized uptake value (SUVmax) of the tumor lesion.
For therapy monitoring and dosimetry estimation, distribution of
the therapeutic agent [177Lu]DOTATATE was assessed dynamical-
ly with a dual-headed scintillation camera (E.cam, Siemens Medical
Solution, 16 mm NaI(Tl) crystal) equipped with medium energy
parallel hole collimators. Patients were positioned on the camera
table in supine feet-first orientation. Detector heads were positioned
in the anterior and posterior locations. An energy window was
centered on the major gamma photon peak of the Lu-177 decay
series (208 keV, width=15 %), together with additional windows
(240 keV, width=10 %; 170 keV, width=15 %) to allow for scatter
correction using the triple energy window method. Upon beginning
the [177Lu]DOATATE infusion, a dynamic sequence of 12 planar
frames (of 5 min each) was initiated in a 128×128 matrix of
4.8 mm pixels. Thereafter, whole-body images were acquired over
20 min in a 1024×256 matrix of 2.4 mm pixels at approximately 1,
24, 48, and 72 h post injection (or day 0, 1, 2, and 3 p.i.). An
example series of posterior images is shown in Fig. 1.
The patient’s urine was collected from a bladder catheter
(female patients) or urine bottle (male patients) from the start of
the infusion until the start of the first whole-body scan at
approximately 1 h post injection to determine the net activity in
the early images. For that purpose, the activity of 1-ml portions of
the urine samples was measured with a high purity semi-conductor
Germanium detector (Canberra Industries Inc. Model Gr0820) from
which the total activity of the entire collected volume was
calculated.
Planar Quantification
Scatter correction was performed according to the triple energy
window method described by Ichihara et al. [11]. For attenuation
correction, the patient thickness and the kidney thickness were
measured from the CT image, which had been obtained during
diagnostic imaging. Furthermore, the kidney mass was determined
for later dose calculations.
The activity Aj in a source region j was calculated according to
Eq. 1. Attenuation correction was therein performed according to
A. Delker et al.: Early Measurements Affect Kidney Dosimetry in Lu-177 PRRT
the method published by Fleming et al. [12] and as suggested in the
MIRD 16 Pamphlet [13] for isolated single source regions, with a
correction for the source region attenuation fj and the source
thickness xj with the coefficient μj.
Aj ¼
ffiffiffiffiffiffiffiffiffiffi
IAIP
e−μex
r μ jx j=2
 
Csinh μ jx j=2
  ¼
ffiffiffiffiffiffiffiffiffiffi
IAIP
e−μex
r
f j
C
ð1Þ
where IA and IP are the counts per second (cps) detected in the
anterior and posterior region of interest (ROI) j. The exponential
term e−μex represents the transmission factor for a patient with the
total thickness x (cm) and with an individual attenuation value μe.
For the attenuation coefficients, we used the four component soft
tissue values obtained from the XCOM cross section database [14].
C is the calibration factor for each individual patient and therapy
cycle in cps/Bq determined from the sum of counts in the first
whole-body planar image, divided by the net remaining activity in
this image.
To calculate the kidney counts, ROIs were drawn around
the organ boundaries to scintigraphy, and attenuation corrected
as described above. For background correction, an ROI was
placed in an area without specific tracer accumulation, such as
the lower abdomen or the thigh and subtracted with the method
described by Kojima et al. [15] and presented in the MIRD 16
Pamphlet as BBackground Subtraction: A Single Well-Defined
Source Region Surrounded by Regions of Background
Activity^ to avoid over subtraction of background activity.
Finally, the sum of counts from a whole-body ROI at day 0
were divided by the total administered activity, less the activity
lost to micturition (1.3±0.5 GBq, range 0.1–2.2 GBq). Only
those organs without allocation of extra activity uptake due to
overlay effects were analyzed; the right kidney was overlapped
by liver activity in many projection images. Therefore, we
decided to investigate solely the effect of early measurement
time points for the left kidney. Patient data was excluded from
this study when overlay of extrarenal activity was present in
the images of the left kidney.
Dose Calculations
The dose calculations in this work were performed according to the
MIRD scheme [16]. The radiation dose is assessed by describing
activity in source regions which irradiate target regions, as well as
self-radiation of the target. The dose to a given target area is then
calculated as the sum of all dose fractions from the source regions.
To simplify the calculation, we assumed that most of the radiation
damage to organs is caused by the beta radiation of Lu-177 and
therefore neglected the irradiation by gamma-photons arising from
other source regions. The mean absorbed dose D to the kidney was
then calculated by:
D ¼ eA S ð2Þ
eA is the accumulated activity in the kidney (as a measure of all
nuclear transitions) and S is the mean absorbed dose per unit
accumulated activity (or the mean absorbed dose per nuclear
transition). We applied a three-phase model (TrBi-exp) consisting
of a linear increase to the maximum within the initial minutes of the
infusion and a bi-exponential decline describing a rapid distribution
phase and a slow washout/elimination phase. The bi-exponential
function was fitted using the nonlinear least squares method in
MATLAB (R2011a, The MathWorks, Inc.). To obtain the sum of
all nuclear transitions, this three-phase model was integrated over
time to infinity. The cumulated activity eA was then used to
estimate the absorbed dose D together with the kidney-specific S
value for Lu-177 obtained from the RADAR website [17]. A
rescaling to the individual patient kidney mass was performed
according to [18]
S patientð Þ ¼ S MIRDð Þm MIRDð Þ
m patientð Þ ð3Þ
using the MIRD mass and S values from the kidneys of the adult
phantoms [19].
Fig. 1 Posterior planar whole-body view approx. 1, 24, 48, and 72 h (from left to right) after administration of
[177Lu]DOTATATE.
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Investigating the Effect of Early Time Points
The integrated activity of TrBi-exp served as baseline for
evaluating kidney doses calculated from four whole-body static
images at approx. 1, 24, 48, and 72 h p.i. (4P-fit) or only the last
three whole-body images (3P-fit). We compared a mono-
exponential function with two parameters
f 0 tð Þ ¼ p1e−p2t ð4Þ
as the null hypothesis, with a set of three-parametrical fit
functions as the alternate hypothesis, with fit parameters pi and—in
the case of Eq. 5b as in [20, 21]—with a separate consideration of
the physical decay constant λphys
f 1 tð Þ ¼ p1 e −p2tð Þ þ e −p3tð Þ
 
ð5aÞ
f 2 tð Þ ¼ p1e− p2þλphysð Þt þ p3e−λphyst ð5bÞ
The most appropriate model fm (with m being 0, 1, or 2, as
defined in equations 4 and 5) was then chosen by performing the F
test [20]. For the null hypothesis (null) and the alternative
hypothesis (alt), the squares of the residuals between fitted model
and measured data points were summed yielding SSRnull and
SSRalt. The corresponding degrees of freedom, DFnull and DFalt,
were calculated by subtracting the number of fit parameters from
the number of available measurement points. The F value was then
obtained by:
F ¼ SSRnull−SSRaltð Þ DFalt
DFnull−DFaltð Þ SSRalt ð6Þ
If the p value was under the significance level of α=0.05, the
null hypotheses was rejected, and the alternate model was used.
The corrected Akaike Information Criterion (AICc), which is
proposed by Glatting et al. [20] and Kletting et al. [22], is not
here feasible, since AICc requires at least three more data points
than the number of parameters. For the case of the 3P-fit, we used
the mono-exponential function (Eq. 4) with two parameters to
increase the probability for successful fitting of noisy data by
providing a model which has fewer fit parameters than the number
of available data points. Using the model fm which was selected by
the F test for each individual patient j, we then determined the
percentage deviation of the accumulated activity eAm; j relative to the
accumulated activity eATrBi; j of the baseline model TrBi-exp:
%DEV j ¼
eAm; j − eATrBi; j
eATrBi; j
 100 ð7Þ
Thus, a negative %DEV would indicate underestimation and a
positive %DEV overestimation of the real dose. We calculated the
corresponding mean deviation from baseline for all n patients using
the appropriate model fm for each patient j as selected by the F test:
M ¼ 1
n
Xn
j¼1
%DEV j
  ¼ 1
n
Xn
j¼1
eAm; j− eATrBi; j
eATrBi; j

 100 ð8Þ
Results
Calculated Dose with TrBi-exp
All bi-exponential curve fits succeeded, with a mean coeffi-
cient of determination (R2) value of 0.995±0.010 and minimum
R2 of 0.973. Data for a representative kidney time activity
curve is shown in Fig. 2, with the bi-exponential fit in green.
This bi-exponential consists of two phases, which can interfere
during the first hours. The population mean effective half live
T1/2 was 25.8±12.0 min for the fast phase and 63.9±17.6 h for
the slow phase. Using the TrBi-exp model, the mean calculated
dose of all 105 patient datasets was 5.7±2.1 Gy (range 2.5–
13.8 Gy), which gave a mean kidney dose of 0.8±0.3 Gy/GBq
administered. Because TrBi-exp is a linear combination of
three functions, the mean dose factors and the percentage
contribution to the total dose can be specified separately
(Table 1). The kidney masses used for mass correction of the S
values according to Eq. 3 ranged from 104 to 396 g, with a
mean value of 186±45 g.
Dosimetry Using Four Whole-Body Planar Image
Time Points (4P-fit)
Before calculating the accumulated activity from only four
late scintigraphy measurements, the best fitting of a set of
models was chosen with the F test, as described above. In
five of 105 cases, the model f1 (Eq. 5a) was favored instead
of the mono-exponential function, for which an example is
shown in Fig. 3a. In this graph, the bi-exponential part of the
baseline function (green), mono-exponential (cyan) and f1(t)
(purple) functions are visualized. In most cases, the
alternative models were rejected, as illustrated in Fig. 3b,
where the baseline (green) and the mono-exponential (cyan)
fits are plotted together with the fits onto model f1(t)
(purple). Using the matching fit model for each kidney the
mean R2 was 0.965±0.032 for the 4P-fit. Analyzing the fit
parameters indicated an initial mean activity from parameter
p1 in the kidneys of 153.8±56.1 MBq (range 71–389 MBq).
For the slow washout parameter, the mean half-life for 4P-fit
was 46.3±15.4 h (range 21.5–90.5 h). The calculated dose
with these parameters was 5.0±1.9 Gy (range 2.5–11.3 Gy).
Dosimetry Using 3 Whole-Body Planar Image
Time Points (3P-fit)
Omitting the first measurement point at approx. 1 h p.i. and
using the mono-exponential fit (3P-fit), the mean R2 was
0.983±0.030. Analysis of the fit parameters indicated a mean
initial activity of 126.5±39.2 MBq (range 45–258 MBq) in
the kidneys and a mean effective half-life of 63.3±17.0 h
(range 34.1–115.1 h). The resulting mean dose was 5.6
±2.1 Gy (range 2.5–14.1 Gy).
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Comparison of Dose Estimation Approaches
with Baseline
The deviation of the dose calculated with 3P-fit (blue) and
4P-fit (red) from the dose calculated with TrBi-exp is
presented for each of the 105 kidneys in Fig. 4a. In only 7
of 105 datasets was the absolute deviation from the
calculated dose higher when the first measurement point
was omitted. We saw a maximum absolute deviation of
41.1 % with the 4P-fit compared to a maximum of 13.8 %
with 3P-fit, calculated relative to the baseline method. The
mean absolute percentage deviation was 12.4±9.2 % with
four points and 3.1±2.5 % with three points. With the
exception of six patients, the calculated dose with four
points was always underestimated, whereas the calculation
with three time points underestimated dose in 65 and
overestimated in 40 cases. Calculated doses of the baseline
model TrBi-exp, 4P-fit, and 3P-fit are shown in Fig. 4b. The
mean dose value with four late points was significantly
decreased compared to the other two methods.
Discussion
Considering the generally impaired health status of most
patients undergoing PRRT, it is mandatory to obtain reliable
dosimetric data with a minimal number of measurements. As
in previous dosimetry investigations [23–25], we decided to
conclude dosimetry monitoring at 72 h because of logistic
reasons. This work is based on the assumption that all
kinetic models are valid beyond the last data point at 72 h
p.i. Although we have no proof that this assumption holds,
others who had measurements available over a longer time
interval, e.g., until approximately 168 h [9, 26, 27], have not
observed a deviation of data and exponential model at later
times. We therefore assume that the models utilized in this
work are suitable descriptions for estimation of the kidney
dose. The contribution of the first 72 h to the kidney dose
calculated using our proposed reference model TrBi-exp was
approximately 54.6±9.2 % (range 34.1–73.7 %).
The limitation to planar scintigraphies is a potential
weakness of this study since quantitation of planar scintig-
raphy is subject to several caveats arising from attenuation
and overlap of tissues. Especially, uncertainties due to
overlap could be prevented, and radionuclide concentration
calculations could be improved by performing 3D dosimetry
based on quantitative SPECT/CT measurements [27]. Recent
SPECT/CT studies utilizing the radionuclide Lu-177 report-
ed encouraging accuracies and methods in quantitative
imaging [28, 29]. The patient group in this study was pre-
selected to contain no obvious kidney overlay in the planar
images; therefore, we did not expect a major influence of
superpositioned organs. Dosimetry from SPECT/CT images
will be addressed in future investigations.
In this paper, we studied the effect of reducing the
number of time samples on the outcome of the dosimetry
calculations, based on various kinetic models and truncation
of the data to as few as three time points. Present data show
that the concentration of radioactivity derived from
[177Lu]DOTATATE in the kidneys is not well described
using a single exponential function; we tested several simple
multi-phase models, the best of which proved to be a model
composed of three phases. Here, the fast initial uptake phase
Table 1. Absolute and relative contribution of the single phases to the total dose function TrBi-exp. Each value was obtained from 105 kidneys
Function Mean [Gy] SD [Gy] Min. [Gy] Max. [Gy] Rel. [%]
Linear phase 0.03 0.01 0.01 0.08 0.6
Fast phase 0.03 0.03 0.003 0.19 0.6
Slow phase 5.6 2.1 2.5 13.8 98.9
TrBi-exp (all) 5.7 2.1 2.5 13.8 100
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Fig. 2 a Time activity curve of the left kidney of a patient with dynamic planar measurement of [177Lu]DOTATATE within the
first hour (filled circles) and planar whole body scintigraphies up to 70 h post injection (open squares). The bi-exponential fit is
plotted in green and its two exponentials, which represent the different phase fractions, are plotted in blue (fast; T1/2=31 min)
and red (slow; T1/2=63 h). b This plot focuses on the early phase within the first 6 h indicated by the dashed rectangular area in
(a) so as to visualize the linear increase to the maximum within the initial minutes of the infusion.
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was described by a linear increase from time 0 to the time of
maximum tracer concentration in the kidneys and was
followed by a linear combination of two exponential
functions, representing phases of elimination with different
time characteristics. For the group of patients, this model
gave mean effective half-lives of 25.8±12.0 min for the fast
phase and 63.9±17.6 h for the slow phase. In pharmacoki-
netic studies, such results are generally interpreted to reveal
a distribution phase followed by a slow elimination phase.
Comparing the mean relative contributions to the total
absorbed dose (Table 1), we found that almost the entire
dose (98.9 %) is attributable to the slow phase component.
The mean dose values for the left kidney per therapy cycle
were 5.7±2.1 Gy (0.8±0.3 Gy/GBq), which is in good
accordance to previous studies [26, 30, 31]. In agreement
with Sandstroem et al. [27] and others [32], we noticed a
wide range of kidney doses (2.5–13.8 Gy; median 5.3 Gy),
likely reflecting a wide range of renal absorption and
elimination parameters of the multi-phase kidney activity
kinetics in this heterogeneous population. The occurrence of
this observed dose variation, where individuals at the high
end might easily encounter radiotoxicity, substantiates the
need for an individualization of the peptide radionuclide
receptor therapy.
A systematic analysis of the observed multi-phase model
yielded the following results; based on earlier reports [13,
27], we at first expected an overall higher dose if the first
data point was measured during the fast elimination phase.
Comparing the mean initial activities in the kidney from 4P-
fit (153.8±56.1 MBq) and 3P-fit (126.5±39.2 MBq), indi-
cated a 21.3 % higher calculated dose, as expected for the
4P-fit. Comparing the time activity curve of one represen-
tative patient’s dataset (Fig. 5) indicated a considerable
overestimation of initial uptake, propagating to an artifact of
increased area under the curve within the first days after
treatment. However, we also observed a steeper descent of
the exponential curve caused by the elevated first data point,
which led to systematic underestimation of the half-life of
the exponential. Hence, when integrating these exponentials
to infinity, the area under the entire curve (i.e., the total
dose) would consequently be substantially smaller than as
predicted by the baseline or the 3P-fit models. Consequent
underestimation of the total calculated dose is illustrated by
comparison of Fig. 4.
This finding is in concordance with the earlier observa-
tions of Guerriero et al. [23], who also investigated the
accuracy of estimated dose when certain data points were
omitted. Their remarks on the inadequate number of
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Fig. 3 Example of fit models with four static planar kidney measurement points. a The mono-exponential fit is plotted in cyan
(R2=0.968) and function f1(t) (Eq. 5a) is plotted in purple (R
2=0.997). The F test indicated f1(t) to be superior in this case
(PG0.025). For comparison, TrBi-exp is plotted in green. b A representative patient in whom the F test rejected f1(t) . Here, the
mono-exponential fit (cyan; R2=0.994) was superior to the model f1(t) (Eq. 5a, R
2=0.541).
Fig. 4 a Comparison of the percentage deviation to TrBi-exp with all four planar measurement time points (4P-fit; red) or only
the last three planar measurement points (3P-fit; blue) of all 105 patient datasets. A positive value indicates an overestimation
and a negative value an underestimation of the dose. b Boxplots of the dose calculated with TrBi-exp (left), 4P-fit (middle), and
3P-fit (right). Outliers are plotted individually (red).
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available data points to describe multiple phases arose from
SPECT images at comparable time points as in the present
work, except that no dynamic sampling of the initial fast
phase was available to them. Provided with the initial
dynamic data, we concur with their observations.
Furthermore, our data allow us to describe the fast and slow
phases separately and predict a time point after which the
influence of the fast phase onto the overall time activity
curve diminishes. In contrast to [9], where kidney dose was
assessed by four planar images during days 0, 1, 2, and 7,
we did not observe peak activities in the kidneys at day 1 or
later. Omitting the late day 7, data point had a noticeable
effect on the estimated kidney dose in their work. As this
situation is similar to using the 4P-fit in our present work but
with day 2 constituting the latest time point, our findings
indicate that this effect may rather be related to the mixture
of the fast and slow retention phases in the early data points,
but in concordance with [9], the effect could be weakened
when data points later than day 3 are included.
To study the fast-phase influence on the day 0 whole-
body image in some detail, we calculated the ratio between
fast and slow phases from the bi-exponential model. The
mean time of the first whole-body measurement was 1.2
±0.1 h after injection, when the mean relative ratio between
the fast and slow phases was 28.1±23.9 %. The mean time
point at which this ratio fell below an arbitrary value of 5 %
was 2.4 h p.i. (max 5.1 h), whereupon the contribution of the
first phase might safely be ignored. Figure 6 illustrates the
effect on treatment day 0 of this influenced measurement
onto the percentage dose deviation (compared to TrBi-exp),
when the total dose was calculated with (4P-fit, red) or
without (3P-fit, blue) the day 0 measurement. The
Spearman’s test gave ρ of 0.91 (4P-fit), indicating a very
strong correlation between the dose deviation and the
contribution of the fast retention phase to the day 0
measurement. In the case of the three time points (3P-fit),
no such correlation was found (ρ=0.01).
The coefficient of determination R2 of the 4P-fit was
consistently high (circa 0.97), which would not in itself alert
to this bias. Nevertheless, the utilization of more sophisti-
cated fitting algorithms, which assign individual weights to
each measurement point, is certainly sufficient to reduce the
mismatch between treatment day measurements and the
chosen mono-exponential kinetic model. Our observations
confirm that high R2 values cannot be relied upon as proof of
model fitness but that curve fits should be carefully checked
by an experienced reader. This is illustrated in Fig. 5, where
the 4P-fit results in R2 of 0.95, although this fit clearly does
not represent the true situation. The inadequacy of R2 as an
indicator for the fit quality of nonlinear functions is in
accordance with Spiess et al. [33]. When the same model is
applied to only a subgroup of these data, i.e., omitting the
treatment day whole-body scan, the accuracy of the results
could be significantly improved. Nevertheless, limitations
could arise from this reduction of data especially if one of
the remaining measurements is not available due to a
hardware failure or patient discomfort. It is generally
understood that at least three data points are needed for
modelling an exponential phase, as noted by Lassmann et al.
[34].
A mean dose deviation from the 4P-fit of 12.4±9.2 % in a
single therapy cycle is unlikely to be a factor in the risk for
radiation-induced nephropathy. However, an accumulation
of such dose underestimations in multiple therapy cycles
could well lead to a substantial and relevant underestimation
of total radiation dose to the kidneys. In three of 105
individual cases, we observed a dose deviation for the 4P-fit
of up to 40 %, corresponding to 3 Gy in a single cycle (see
Fig. 4a). In seven of 105 datasets, the underestimation
exceeded 2 Gy. If dose estimates from individuals are used
for designing dosimetry-supported individualized therapies,
the observed underestimations would cause ill-planning of
therapeutic doses of subsequent cycles. Hence, the risk of
receiving a critically high radiation dose increases signifi-
cantly for patients across the treatment cycle.
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Fig. 5 Comparison of fits of planar scintigraphy data with
four points (4P-fit, cyan), 3 points (3P-fit, dashed black), and
the bi-exponential fit (Bi-exp, green) including the dynamic
data during the first 30 min after infusion. The abscissa is
extended to distinguish the gradients of the curves.
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Fig. 6 Percentage dose deviation compared to the baseline
function TrBi-exp with four time points (red) and the last three
time-points (blue) as functions of the ratio of fast to slow
phases at the first whole-body measurement day. A linear
regression is shown for both cases.
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Conclusion and Outlook
We studied the effect of reducing the number of measure-
ment times on the outcome of dosimetry calculations based
on various multi-phase descriptions of the kidney activity
following a [177Lu]DOTATATE treatment cycle in a series
of 64 NET patients. We found that the majority of the
kidney dose occurs during the slow washout phase, which is
integrated to infinity, as in conventional pharmacokinetic
models. We also found that interference of early measure-
ments by the fast washout phase biases the results,
sometimes resulting in severe underestimation of the kidney
dose. This work demonstrates that the accuracy of dosimet-
ric values for the kidneys largely depends on a proper
determination of the slow phase for renal washout. However,
careful selection of data points avoids errors arising from
integration of unsuitable early data, which may be affected
by the fast phase. These observations support reducing the
number of scintigraphy measurements without compromis-
ing the accuracy of image-based dosimetry. These findings
should facilitate optimized dosimetry scanning protocols,
while minimizing the work load for staff and patients.
Scintigraphy results may generalize to quantitative SPECT
measurements, which are not dependent on the whole-body
calibration. Thus, we recommend starting the first dosimetric
measurement 24 h after radiotherapeutic agent injection.
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Abstract
Purpose Dosimetry is critical to achieve the optimal therapeu-
tic effect of radioligand therapy (RLT) with limited side ef-
fects. Our aim was to perform image-based absorbed dose
calculation for the new PSMA ligand 177Lu-DKFZ-PSMA-
617 in support of its use for the treatment of metastatic pros-
tate cancer.
Methods Whole-body planar images and SPECT/CT images
of the abdomen were acquired in five patients (mean age
68 years) for during two treatment cycles at approximately
1, 24, 48 and 72 h after administration of 3.6 GBq (range
3.4 to 3.9 GBq) 177Lu-DKFZ-PSMA-617. Quantitative 3D
SPECTOSEM reconstruction was performed with corrections
for photon scatter, photon attenuation and detector blurring. A
camera-specific calibration factor derived from phantom mea-
surements was used for quantitation. Absorbed doses were
calculated for various organs from the images using a combi-
nation of linear approximation, exponential fit, and target-
specific S values, in accordance with the MIRD scheme.
Absorbed doses to bone marrow were estimated from planar
and SPECT images and with consideration of the blood sam-
pling method according to the EANM guidelines.
Results The average (± SD) absorbed doses per cycle were
2.2±0.6 Gy for the kidneys (0.6 Gy/GBq), 5.1±1.8 Gy for the
salivary glands (1.4 Gy/GBq), 0.4±0.2 Gy for the liver
(0.1 Gy/GBq), 0.4±0.1 Gy for the spleen (0.1 Gy/GBq), and
44±19 mGy for the bone marrow (0.012 Gy/GBq). The organ
absorbed doses did not differ significantly between cycles.
The critical absorbed dose reported for the kidneys (23 Gy)
was not reached in any patient. At 24 h there was increased
uptake in the colon with 50 – 70 % overlap to the kidneys on
planar images. Absorbed doses for tumour lesions ranged be-
tween 1.2 and 47.5 Gy (13.1 Gy/GBq) per cycle.
Conclusion The salivary glands and kidneys showed high,
but not critical, absorbed doses after RLT with 177Lu-DKFZ-
PSMA-617. We suggest that 177Lu-DKFZ-PSMA-617 is suit-
able for radiotherapy, offering tumour-to-kidney ratios com-
parable to those with RLT agents currently available for the
treatment of neuroendocrine tumours. Our dosimetry results
suggest that 177Lu-DKFZ-PSMA-617 treatment with higher
activities and more cycles is possible without the risk of dam-
aging the kidneys.
Keywords Prostate cancer . PSMA .mCRPC .
Lutetium-177 . Dosimetry . Radioligand radiation therapy
Introduction
After lung cancer, prostate cancer (PC) is the second most
common primary tumour affecting men worldwide. Despite
improvements in therapy over the past decades, PC tends to
become highly aggressive in most patients over time, ulti-
mately causing the death of more than 250.000 men each year
worldwide [1]. Radionuclide therapy has gained increasing
importance for the treatment of metastatic, castration-
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resistant PC (mCRPC) with the approval of the use of 223Ra.
Systemic administration of the calcium ion mimetic 223Ra
improves survival in mCRPC patients with symptomatic bone
metastases [2]. However, about one-third of mCRPC patients
present with lymph node or visceral metastases, which are gen-
erally associated with a poor prognosis, and are unresponsive to
bone-seeking radiopharmaceuticals [3]. Ligands for the
prostate-specific membrane antigen (PSMA) have recently
been developed to target systemic disease. PSMA is
overexpressed in almost all prostate tumours, and is therefore
an outstanding target for radionuclide therapy, especially since
its expression increases further in patients with dedifferentiated,
metastatic or hormone-refractory disease [4]. Several trials have
shown effective reductions in tumour burden and serum
prostate-specific antigen levels after administration of therapeu-
tically radiolabelled PSMA targeting drugs [5–7].
Based upon promising initial results, a concerted effort has
led to the design of PSMA ligands with improved safety pro-
files. Of several new candidates, 177Lu-labelled DKFZ-
PSMA-617 binds with 2.3 nM to PSMA in vitro, and has
enhanced binding to tumour in vivo, with relatively reduced
uptake in the kidney, an organ at particular risk of treatment-
induced toxicity [8]. Before finding general use in the clinic,
the dosimetry of 177Lu-DKFZ-PSMA-617must be defined, so
as to enable administration of the optimal treatment activity,
allowing tumour irradiation with the maximum absorbed dose
without exceeding the recommended thresholds for critical
organs. The mode of decay of the radionuclide 177Lu presents
a particular advantage for therapeutic dosimetry, as its beta
emission provides tumour radiation, while its gamma compo-
nent allows uptake quantification by serial scintigraphy and
SPECT. The aim of this study was to perform image-based
absorbed dose calculations for critical organs during two cy-
cles of 177Lu-DKFZ-PSMA-617 administration in a group of
mCRPC patients, thus aiding the design of an optimal treat-
ment protocol with minimal toxicity for nontarget organs.
Material and methods
Image acquisition
All data were acquired on a dual-headed Symbia T2 SPECT/
CT system (Siemens Medical Solutions, Erlangen, Germany)
equipped with medium-energy low-penetration (MELP) col-
limators and opposing (180° mode) detector heads. Image
data were recorded in whole-body planar scintigraphy and
SPECT or SPECT/CT mode, i.e. with a SPECT recording
followed by a CT acquisition (130 kVp with voxels of size
1 mm×1 mm×5 mm) for SPECT attenuation correction and
assessment of patient anatomy. The acquisition parameters are
given in Table 1. Energy windows were chosen as described
by Delker et al. [9]: the emission window was centred at
208 keV (width 15 %, the main upper photopeak of the
177Lu decay series), the upper scatter window at 240 keV
(width 10 %) and the lower scatter window at 170 keV (width
15 %).
Image reconstruction
Images were reconstructed using a rotation-based one-step-
late penalized ordered subsets expectation maximization algo-
rithm which included a gaussian diffusion model to compen-
sate for distance-dependent detector blur [10–13]. The
distance-dependent point spread function was derived from
measurements of a 177Lu point source positioned at different
distances from the detector surface. No corrections for dead
time, partial volume and spillover effects were performed. A
scatter estimate was derived from the adjacent scatter energy
windows with the triple-energy window method, and imple-
mented into the reconstruction algorithm [14]. For attenuation
correction, the CT image was segmented based on the method
described by Bai et al. [15] by assigning an appropriate
Hounsfield unit to each tissue density value, with further con-
version to a gamma energy-dependent mass attenuation coef-
ficient, μ. For this purpose we defined our attenuation CT
measurements using a tissue characterization phantom
(Gammex 467; Gammex, Inc., Middleton, WI). The final im-
age reconstruction is described by Eq. 1,
xkþ1j ¼ xkj
1X
i∈Sn
ai j þ β P xkj
  X
i∈Sn
ai j
yiX
j
ai jxkj
 
þ si
ð1Þ
where P(xj
k) denotes a quadratic filter operation onto voxel j
using its 5×5×5 neighbouring voxels, and Sn is the subset of
projections to be considered. A penalty weight factor βwas of
low magnitude in order to slightly reduce the Gibbs artefacts
without greatly sacrificing resolution. According to Eq. 1, the
final image xk after iteration k contained the number of recon-
structed counts per voxel. Quantitative emission images, ob-
tained as activity concentration per unit volume (i.e. q in
Table 1 Acquisition parameters
Parameter Value
Planar whole-body acquisition
Matrix 1024×256
Pixel size (mm) 2.4×2.4
Total scan time (min) 20
SPECT acquisition
Matrix 128×128
Pixel size (mm) 4.8×4.8
Number of steps 128 total (64 per head)
Step duration (s) 20 (40 for calibration)
Approximate total scan time (min) 22
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Becquerels per millilitre) in each voxel j, were then calculated
as the product of the duration of each tomographic step T
(seconds), the voxel volume V (millilitres), and the calibration
factor C Becquerels per counts per second):
qj ¼
x j
T ⋅V
⋅C ð2Þ
Calibration
The calibration factor C in Eq. 2 was derived from a cylindri-
cal phantom with a volume of 6.7 L and an internal diameter
of 22 cm, which was homogeneously filled with a solution
containing a total 177Lu activity of 637 MBq (Q=92.3 kBq/
mL). A SPECT acquisition was performed with 40 s per step,
followed by CT imaging, as described above. As can be seen
from Eq. 2, the calibration factor does not change with varying
step length of the SPECT projections. To avoid a noise-related
bias of this factor we decided to achieve an increased number
of counts by prolonging the calibration measurements com-
pared to the patient acquisitions. After image reconstruction,
C was calculated using Eq. 2, knowing q=Q, T=40 s and V=
0.48 cm3.
Quantification of recovery
The reproducibility of quantitative values was assessed
using a hot-sphere phantom (NEMA-NM2-2001) contain-
ing six spheres of internal diameters (and corresponding
volumes) of 37 mm (26.5 mL), 28 mm (11.5 mL), 22 mm
(5.6 mL), 17 mm (2.6 mL), 13 mm (1.2 mL) and 10 mm
(0.5 mL) in a homogeneously filled background volume.
A 177Lu activity of 38.1 MBq was added to a measuring
cylinder containing 50.8 mL water (75.6 kBq/mL); this
solution was used to fill the spheres. A 177Lu activity of
725.4 MBq was mixed in the 9.7-L background volume
(7.5 kBq/mL), resulting in a hot sphere to background
radioactivity concentration ratio of approximately 10:1.
The NEMA phantom was then scanned using the param-
eters given in Table 1, followed by a CT acquisition. After
reconstruction and calibration, the images were further
analysed using PMOD software (v.3.603; PMOD Technol-
ogies Ltd.). A large cylindrical background volume of
interest (VOI) was positioned in the homogeneously filled
lower area of the phantom, at least 3 cm from the bound-
aries. A VOI for each hot sphere was precisely drawn onto
the contours of the coregistered CT image. From the mean
reconstructed activity concentration q in each VOI, and
knowing its true activity concentration, Q, the correspond-
ing recovery coefficients, R, were calculated as q/
Q × 100 %for the background and for each sphere.
Patients and therapy
Between September 2014 and April 2015 five patients with
mCRPC refractory to standard therapy (mean age 68 years,
range 54 to 81 years) each received two cycles of radioligand
therapy (RLT) with 177Lu-DKFZ-PSMA-617 administered at
a mean activity of 3.6 GBq (range 3.4 to 3.9 GBq) per cycle.
An interval of 10 weeks between the cycles was chosen to
allow assessment of subacute toxicity at 4 to 8 weeks after
RLT [16]. All patients demonstrated PSMA-avid lesions on
pretherapeutic 68Ga-HBED-PSMA PET/CT. Each treatment
was performed during a 4-day stay in the Nuclear Medicine
Ward, in accordance with German radiation protection laws.
Patients received 50 mg prednisolone and 1 L of 0.9 % NaCl
intravenously daily until discharge. In order to reduce blood
flow and tracer uptake in the parotic and submandibular
glands, ice packs were applied locally for 6 h after each
RLT. Patients were monitored each day as inpatients, with
physical examination and routine blood tests for electrolytes,
haematology, liver and kidney function. Patients had serial
follow-up examinations including routine blood test at inter-
vals of 2 to 4 weeks after RLT.
For each SPECT scan, patients were positioned supine and
feet-first on the camera table. The radiopharmaceutical was
infused intravenously in 30 mL saline at a flow rate of
100 mL/h. Blood samples were collected from the contralat-
eral side every 10 min until the start of the first whole-body
scintigraphy scan at 1 h after the start of infusion, and once on
each subsequent measurement day. Approximately 1 h after
the start of the infusion, a whole-body planar scintigraphy
scan was acquired and calibrated with the settings described
by Delker et al. [9], followed by a SPECT/CT scan of the
abdomen. Further planar whole-body and abdominal SPECT
measurements were acquired on subsequent days at approxi-
mately 24, 48 and 72 h after injection. The acquisition param-
eters are given in Table 1. The dead time reported by the
camera was approximately 8 % on day 0 and approximately
3 % on day 1. Because the CTacquisition was performed only
on the therapy day, for attenuation correction, the uncorrected
SPECT images for each subsequent emission recording were
individually coregistered to the single CT scan using the rigid
matching function in the PMOD Fusion Tool with manual
correction if deemed necessary. The final reconstruction of
quantitative SPECT images was performed using corrections
for photon scatter, photon attenuation and distance-dependent
detector blur, followed by voxelwise application of the cali-
bration factor presented above. Dosimetry was performed as
part of the clinical routine. All patients gave written consent to
undergo RLT with subsequent dose evaluation. Dose estima-
tions presented in this study were acquired retrospectively
from anonymized patient data. The retrospective study proto-
col was approved by the local ethics committee, and written
informed consent for entry into the study was waived.
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Absorbed dose calculations
To calculate the total radioactivity in the kidneys, liver,
spleen and selected tumour lesions, time–activity curves,
obtained from a VOI analysis of the four serial quanti-
tative SPECT images modelled as described by Delker
et al. [9], with a linear interpolation of activity between
the start of infusion (t0=0) and the time (t1) of the first
SPECT/CT measurement, a linear interpolation between
t1 and the time of the SPECT scan at approximately
24 h (t2), followed by a monoexponential nonlinear
least squares fit to the last three data points using
MATLAB (R2011a; The MathWorks, Inc., Natick, MA):
q tð Þ ¼
α1t 0 ≤ t < t1
α2t þ q t1ð Þ t1 ≤ t < t2
α3e
γt t ≥ t2
8<
: ð3Þ
To estimate the absorbed dose, this model time–activity
curve was time-integrated and multiplied by the organ specific
S value [17], considering only the self-dose fraction. Further-
more, S values were corrected for individual organ mass [18,
19]. For approximating the absorbed dose to the salivary
glands, the calibrated planar whole-body images were used,
with sphere S values.
Absorbed bone marrow dose estimates were calculat-
ed from the sequences of planar whole-body images
according to the EANM guidelines [20], including the
contributions from the bone marrow self-dose, and cross
irradiation from the major source organs and the re-
mainder of the body. The bone marrow self-dose was
calculated from the activity concentration of the collect-
ed venous blood samples and the red marrow-to-blood
activity concentration ratio derived from the patients
haematocrit by the method of Sgouros [21]. The cross
irradiation from the organs and the remainder of the
body was calculated by the method of Traino et al.
[22] for more than two source organs, using a linear
mass scaling for the cross irradiation from the source
organs and a 177Lu-dependent nonlinear mass scaling
factor for the red marrow and total body.
Results
Image quantification
The analysis of the calibration phantom yielded a calibra-
tion factor of C of 110,058 Bq/cps. The reconstructed
SPECT image of the NEMA phantom superimposed on
the corresponding CT image is shown in Fig. 1a. The
calculated recovery coefficients are shown in Fig. 1b,
and summarized in Table 2.
Dosimetry
The following sections summarize the results of dosimetric
calculations which performed using planar and SPECT image
data and the modelled blood curve measured over 72 h. The
planar whole-body images from a representative patient
(patient 1, first cycle, in Table 3) are shown in Fig. 2. High
uptake was observed in the intestines after approximately
24 h. In the planar images of eight out of ten RLT cycles this
late intestinal uptake overlapped with 50 – 70 % of the kidney
region. From the series of planar whole-body images, the
estimated absorbed dose to the salivary glands was 5.1±1.8 Gy
(1.4 Gy/GBq). The serial quantitative SPECT and SPECT/CT
images from the same patient, superimposed on theCT data from
day 0, are shown in Fig. 3.
In 3D SPECT/CT images tracer accumulation was clearly
seen in the liver, spleen and kidneys, notably in the renal
cortex. From these images the mean absorbed doses per cycle
were determined as 2.2±0.6 Gy (0.6 Gy/GBq) to the kidneys,
0.4±0.2 Gy (0.1 Gy/GBq) to the liver and 0.4 Gy±0.1 Gy
(0.1 Gy/GBq) to the spleen. The organ masses underlying
these absorbed dose estimates were kidneys 156±47 g (range
94 – 236 g), liver 1,265±393 g (range 925 – 1,904 g), spleen
124±40 g (range 66 – 171 g) and salivary glands 38±5 g
(range 31 – 43 g). Uptake in excess of background was also
seen for multiple tumour lesions, with progressive accumula-
tion up to 24 h after injection (Fig. 4a). In tumours the mean (±
SD) absorbed doses were 19.4±13.5 Gy (5.3±3.7 Gy/GBq,
range 5.6 – 46.0 Gy) in 21 representative bone lesions from
the five patients, 15.1±19.2 Gy (4.2±5.3 Gy/GBq, range 1.2 –
47.5 Gy) in seven lymphmetastases from three of the patients,
and 7.5±2.7 Gy (2.1±0.8 Gy/GBq, range 5.9 – 11.5 Gy) in
four soft tissue metastases seen in one patient. The maximum
observed absorbed dose in tumours was 47.5 Gy (13.1 Gy/
GBq). The mean (± SD) calculated tumour-to-kidney ratios
were 9.8±7.9 (maximum 33.7) for bone metastases, 6.0±5.8
(maximum 15.2) for lymph node metastases, and 3.7±1.1
(maximum 5.6) for soft tissue metastases.
The absorbed dose to the bone marrow was calculated
using a combination of organ cross irradiation calculated from
SPECT images, the total unassigned body measurement de-
rived from planar images, and the activity measured in blood
samples (Fig. 4b) [20]. The mean (± SD) bone marrow
absorbed dose in the five patients was 44.0±18.8 mGy (12.1
±5.2 mGy/GBq, range 26.9 – 90.5 mGy) per cycle. Figure 4
shows the time–activity curves in a representative patient. The
absorbed dose estimates for the investigated critical organs of
each individual patient are presented in Table 3.
Correlation
The relationship between absorbed organ dose estimates cal-
culated for each patient from the first treatment cycle and the
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corresponding second cycle absorbed doses are shown in
Fig. 5. There was a very strong correlation between the
absorbed doses of the two cycles, with an overall Pearson’s
rho of 0.97. In particular, organs with the highest absorbed
dose had correlation coefficients of 0.89 (salivary glands)
and 0.87 (kidneys). The mean absorbed dose ratios for the
kidneys were 0.61 Gy/GBq in cycle 1 and 0.60 Gy/GBq in
cycle 2, and for the salivary glands, the mean absorbed dose
ratio was 1.41 Gy/GBq for both cycles.
Discussion
The tumour and healthy organ absorbed doses for 177Lu-
DKFZ-PSMA-617 were accurately estimated using quanti-
tative SPECT imaging, therefore establishing an optimal
treatment protocol for this new RLT. Several advanced im-
age reconstruction procedures are necessary to obtain the
activity-corrected quantitative images [23]. We first mea-
sured the recovery coefficients of our SPECT images based
on measurements of a known 177Lu activity concentration
in a spherical phantom study, from which we derived the
best possible reconstruction parameters before proceeding
to patient studies. The resultant recovery coefficients of
approximately 80 % for spheres of volume greater than
10 mL (Table 2) are in good agreement with the findings
of a recent study by Sanders et al. of 177Lu SPECT quan-
tification [24]. The lower recovery coefficients found for
the smaller spheres (Fig. 1) most likely arose from the
inherently limited spatial resolution, with signals uncorrect-
ed for partial volume and spill-over effects. For patient data
evaluation, the measurements on day 0 were not included
in the fitting to the monoexponential model function since
superposition of multiple kinetic phases of the pharmaceu-
tical can occur at these early time points [9]. Hence the
influence of errors in these data points, for example the
error from the dead time reported by the SPECT system.
was reduced and only affected the integral of the linear
interpolations. Although the measurement on day 1 was
included in the fit to the model, the effect of the contained
dead time error on the total estimated absorbed dose could
be expected to be of minor magnitude. However, if the
administered activity were substantially increased this issue
would require reconsideration.
By applying this image formation process to the measure-
ments obtained after 177Lu-DKFZ-PSMA-617 RLT SPECT/
CT serial quantitative fusion images were obtained, as shown
in a representative patient in Fig. 3. In accordance with the
findings from diagnostic 68Ga-HBED-PSMA PET/CT [25],
physiological tracer uptake was seen in the abdominal organs,
especially the kidneys. The tracer uptake in tumour lesions
increased from day 0 to day 1 after RLT, in contrast to uptake
in the abdominal organs, which peaked on the day of treat-
ment, and declined thereafter (Fig. 4a), except in the intestines
in which uptake peaked at 48 h. This temporal spatial pattern
indicates specific binding of the 177Lu-DKFZ-PSMA-617 to
PC metastases.
Fig. 1 Fusion of CT and SPECT images of the NEMA phantom (a), and the recovery coefficients (RC) in percent for each sphere and the 784 mL
background (b)
Table 2 Nominal (Q) and reconstructed (q) activity concentrations and
corresponding recovery coefficients for each sphere and the background
Sphere
diameter
(mm)
Volume
(mL)
Activity concentrations
(kBq/mL)
Recovery
coefficient
(%)
Nominal
(Q)
Reconstructed
(q)
37 26.5 75.6 62.0 81
28 11.5 75.6 59.8 78
22 5.6 75.6 55.4 72
17 2.6 75.6 46.2 60
13 1.2 75.6 26.3 34
10 0.5 75.6 9.5 12
Background 784.4 7.5 7.0 93
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In the planar scintigraphy whole-body images, somewhat
elevated 177Lu-DKFZ-PSMA-617 accumulation was ob-
served in the salivary glands and to a lesser extent in the
mucosa. The 177Lu-signal in the intestine (Fig. 2) overlapped
significantly with the kidneys, as has also been reported by
others [25–28], in most of the planar images after RLT. This
overlap would probably result in overestimation of the
absorbed kidney dose if the calculation of dosimetry relied
on planar images, or hybrid SPECT and planar acquisitions.
We therefore recommend that quantitative SPECT acquisition
be used to estimate absorbed kidney doses in 177Lu-DKFZ-
PSMA-617 RLT.
We calculated mean absorbed doses of 0.6 Gy/GBq for the
kidneys, 0.1 Gy/GBq for the liver, 0.1 Gy/GBq for the spleen
and 1.4 Gy/GBq for the salivary glands. The high physiolog-
ical uptake in healthy salivary glands was also noted by
Table 3 Administered activity and absorbed dose values for critical organs in each patient during the first and second cycles of RLT
Patient no. Cycle Activity (GBq) Dose
Left kidney
(Gy/GBq)
Right kidney
(Gy/GBq)
Liver
(Gy/GBq)
Spleen
(Gy/GBq)
Salivary glands
(Gy/GBq)
Bone marrow
(mGy/GBq)
1 First 3.4 0.57 0.58 0.13 0.11 1.60 7.92
1 Second 3.5 0.54 0.74 0.12 0.10 1.36 9.45
2 First 3.8 0.35 0.38 0.06 0.05 1.38 7.68
2 Second 3.7 0.27 0.33 0.06 0.07 1.12 9.23
3 First 3.6 0.73 0.69 0.12 0.12 1.18 25.13
3 Second 3.9 0.71 0.63 0.11 0.10 1.19 9.36
4 First 3.7 0.52 0.57 0.12 0.13 2.11 12.21
4 Second 3.5 0.61 0.57 0.25 0.17 2.48 10.77
5 First 3.6 0.91 0.81 0.09 0.09 0.76 15.81
5 Second 3.6 0.75 0.81 0.06 0.10 0.91 13.79
Mean 3.6 0.60 0.61 0.11 0.10 1.41 12.14
SD 0.1 0.19 0.16 0.06 0.03 0.53 5.24
Fig. 2 Anterior planar whole-
body images at (a) 1, (b) 24, (c)
48, and (d) 72 h in a
representative patient (Table 3,
patient 1, first cycle)
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Zechmann et al. [5], who performed dosimetric estimations
with 131I-labelled PSMA compounds. Although the estimated
maximum cumulative absorbed dose after two cycles was up
to 16 Gy (patient 4) to the salivary glands, none of our patients
complained of xerostomia during follow-up. This is also in
accordance with findings following external beam radiation
therapy, with which irreversible damage to the salivary glands
was observed in only a small group of patients after adminis-
tration of less than 30 – 40 Gy [29, 30]. We found a lower
absorbed dose to the liver following 177Lu-DKFZ-PSMA-617
RLT than was reported for 131I-MIP-1095 [5], and indeed a
lower absorbed dose to all of the evaluated organs than was
seen with the 177Lu-labelled PSMA antibody J-591 [31, 32],
indicating a superior safety profile for 177Lu-DKFZ-PSMA-
617 RLT.
Bone marrow is known to be a tissue at critical risk in
targeted radionuclide therapy [21, 33–35]. In our study, the
absorbed bone marrow dose (0.012 Gy/GBq per cycle), as
estimated from blood and imaging data, was substantially be-
low the critical level of 2 Gy [33], even when taking into
account multiple therapy cycles. This predicts that bone mar-
row toxicity is unlikely to be encountered with 177Lu-DKFZ-
PSMA-617 RLT at the expected activity ranges of several
gigabecquerels per cycle. Nevertheless high radioactivity ac-
cumulations in bone metastases, which lie close to or within
the red marrow, indicate that the true absorbed dose to some
domains of active marrow may be somewhat higher than es-
timated in our study due to spillover.
The kidneys, because of their vital function in elimination
of xenobiotics, are the dose limiting organ in a number of
radioreceptor therapies [36, 37], as in the present study, in
which the dose to the kidneys was the highest amongst the
evaluated abdominal organs. The mean absorbed dose to the
kidneys which was determined in this study for 177Lu-DKFZ-
PSMA-617 is comparable to the dose to the kidneys for 177Lu-
DOTATATE previously reported by Sandström et al. [38] in a
large number of patients (0.6 Gy/GBq) . Moreover, 177Lu-
DKFZ-PSMA-617 showed higher tumour-to-kidney uptake
for all investigated metastases (median 5.8) than 177Lu-
DOTA-JR11 (median 3.3) or 177Lu-DOTATATE (median
1.6) in a previous study byWild et al. [39]. Our results further
suggest that the kidney absorbed dose is comfortably below
commonly- applied dose constraints for that organ (e.g. 23 Gy
as reported by Emami et al. [40]). We therefore conclude that
the amount of 177Lu-DKFZ-PSMA-617 activity administered
in each cycle can safely be increased to achieve an even higher
absorbed tumour dose without causing damage to the kidneys.
The maximum absorbed kidney dose in two cycles was
6.0 Gy (patient 5, Table 3), which is just one-quarter of the
maximal absorbed dose cited above. Based on these results,
Fig. 3 Serial fused SPECT/CT coronal images at (a) 1, (b) 24, (c) 48, and (d) 72 h in the same patient as in Fig. 2
Fig. 4 aDose model curves of activity concentrations in a representative
patient (Table 3, patient 1, first cycle) in one tumour metastasis (red),
kidneys (cyan and dashed blue), spleen (orange) and liver (green). b
Activity concentration curves from the blood samples (red) and the whole
body (green) for calculation of the bone marrow dose
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we predict that it would be safe to increase the administered
activity of the first cycle to, for example, 6 GBq in analogy to
the recommendations of Bodei et al. for peptide receptor ra-
dionuclide therapy in neuroendocrine tumours [41], and adapt
the activity for the following cycles based on the dosimetry to
optimize the tumour dose without reaching the limiting organ
dose. Even in our patient with the highest radiation burden,
this would yield an absorbed kidney dose for the first cycle of
only 5 Gy, well below the safety limit.
Although none of our patients complained of any
effects on salivary gland function after therapy, it is a
matter of concern that increasing the activity might put
the salivary glands at risk. Compared to the radioactive
iodine-labelled compounds such as 131I-MIP-1095 [5],
the novel radiopharmaceutical 177Lu-DKFZ-PSMA-617
has favourable characteristics, imparting lower absorbed
doses to critical organs, including the bone marrow,
which predicts less-severe side effects. Furthermore,
the chelation of 177Lu-based pharmaceuticals can be car-
ried out more quickly and easily compared with 131I-
based labelling, and the physical properties of 177Lu
compared with those of 131I may allow shorter inpatient
stays, improve the quality of dosimetric image data and
reduce therapy-related toxicity. In this study the estimat-
ed absorbed doses (notably for the critical organs) were
highly correlated between the two therapy cycles, as
also observed by Garske et al. [42]. Exceptions are the
estimated bone marrow doses in the two therapy cycles
in patient 3 (25.13 mGy/GBq and 9.36 mGy/GBq) and
the absorbed liver doses in patient 4 (0.12 Gy/GBq and
0.25 Gy/GBq). The calculated absorbed doses for the
other organs in these two patients were consistent be-
tween the therapy cycles. Because of the good correla-
tion in all patients we conclude that the absorbed dose
of the following therapy cycle can be predicted with
sufficient accuracy. This could allow adaptation of the
activity to be administered in the following therapy
cycle.
Conclusion and outlook
Our absorbed dose estimate results derived from five mCRPC
patients each undergoing two cycles of RLT with 177Lu-
DKFZ-PSMA-617 are encouraging. The highest absorbed
dose to healthy organs was observed in the salivary glands,
but this was not associated with any symptoms of xerostomia
during the observation period. The highest accumulated
absorbed kidney dose after both therapy cycles was one-
quarter of the critical dose for that organ. Based on these
findings, we suggest a more aggressive treatment, starting
with an activity of 6.0 GBq and modulating the activity for
the following cycles based on dosimetry to reach a preset
threshold which is assumed save. For optimized dosimetry
we recommend using quantitative SPECT.
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